

New POU dimer configuration mediates antagonistic control of an osteopontin preimplantation enhancer by Oct-4 and Sox-2

Valérie Botquin,¹ Heike Hess, Guy Fuhrmann,² Constantinos Anastassiadis,¹ Michael K. Gross,³ Gerrit Vriend,¹ and Hans R. Schöler^{1,4}

¹Gene Expression Programme, European Molecular Biology Laboratory (EMBL), 69117 Heidelberg, Germany

The POU transcription factor *Oct-4* is expressed specifically in the germ line, pluripotent cells of the pregastrulation embryo and stem cell lines derived from the early embryo. Osteopontin (OPN) is a protein secreted by cells of the preimplantation embryo and contains a GRGDS motif that can bind to specific integrin subtypes and modulate cell adhesion/migration. We show that *Oct-4* and *OPN* are coexpressed in the preimplantation mouse embryo and during differentiation of embryonal cell lines. Immunoprecipitation of the first intron of *OPN* (i-opn) from covalently fixed chromatin of embryonal stem cells by Oct-4-specific antibodies indicates that Oct-4 binds to this fragment in vivo. The i-opn fragment functions as an enhancer in cell lines that resemble cells of the preimplantation embryo. Furthermore, it contains a novel palindromic Oct factor recognition element (PORE) that is composed of an inverted pair of homeodomain-binding sites separated by exactly 5 bp (ATTTG +5 CAAAT). POU proteins can homo- and heterodimerize on the PORE in a configuration that has not been described previously. Strong transcriptional activation of the *OPN* element requires an intact PORE. In contrast, the canonical octamer overlapping with the downstream half of the PORE is not essential. Sox-2 is a transcription factor that contains an HMG box and is coexpressed with Oct-4 in the early mouse embryo. Sox-2 represses Oct-4 mediated activation of i-opn by way of a canonical Sox element that is located close to the PORE. Repression depends on a carboxy-terminal region of Sox-2 that is outside of the HMG box. Expression, DNA binding, and transactivation data are consistent with the hypothesis that *OPN* expression is regulated by Oct-4 and Sox-2 in preimplantation development.

[Key Words: POU; Oct; Sox; osteopontin; preimplantation embryo]

Received March 9, 1998; revised version accepted April 14, 1998.

The fertilized oocyte undergoes cleavage until a uniform cluster of cells, the morula, is formed. The first apparent differentiation occurs as the inner cell mass (ICM) separates from the trophectoderm during blastocoel formation (Gardner 1983). Trophectoderm refers to the epithelial cell layer that encloses the ICM and blastocoel. Subsequently, cells dissociate from the ICM and cover its blastocoelic surface to form the hypoblast (also called primitive endoderm). These cells do not form a well-defined polarized epithelium, eventually loose cell contacts, and contain an extensive rough endoplasmic reticulum, which is often swollen with secretory material (Nadjicka and Hillman 1974). The hypoblast differenti-

ates into the parietal and visceral endoderms (Gardner 1983). Parietal endoderm cells form from hypoblast precursors that migrate and adhere to the thin basal lamina on the inner surface of the trophectoderm. In contrast, visceral endoderm cells do not migrate and consists of a columnar epithelial layer surrounding the late ICM or early epiblast (also called primitive endoderm). Relatively little is known about the molecular signals guiding cell proliferation, differentiation, and migration during establishment of these extraembryonic tissues that arise by the first differentiation events of the embryo.

Oct-4 (also termed *Oct-3* or *Oct3/4*) encodes a POU transcription factor (Okamoto et al. 1990; Rosner et al. 1990; Schöler et al. 1990a,b). DNA binding by POU factors is mediated by the 75-amino-acid POU-specific domain (POU_S) and the 60-amino-acid carboxy-terminal POU homeodomain (POU_{HD}) that is of the C-50 subtype (for review, see Herr and Cleary 1995). POU_S and POU_{HD} are connected by a linker that varies, in sequence and length, in the >20 metazoan POU factors that have been

Present addresses: ²Centre de Neurochimie, Laboratoire de Neurobiologie du Développement et de la Régénération—Centre National de la Recherche Scientifique (LNDP—CNRS) ERS10, 67084 Strasbourg, Cedex, France; ³The Salk Institute for Biological Studies, Molecular Neurobiology Laboratory, La Jolla, California 92037-1099 USA.

⁴Corresponding author.

E-MAIL schoeler@embl-heidelberg.de; FAX 6221-387 518.

Botquin et al.

identified (Verrijzer and Van der Vliet 1993; Wegner et al. 1993; Herr and Cleary 1995). Regions outside the POU domain show no significant sequence homology.

Before gastrulation Oct-4 RNA is expressed in all cells of the embryo proper (Rosner et al. 1990; Schöler et al. 1990b). The proportion of embryonic cells expressing Oct-4 mRNA gradually declines as the trophoctodermal and somatic lineages are established, and Oct-4 transcripts are eventually confined to the male and female germ cell lineages (Rosner et al. 1990; Schöler et al. 1990b; Yeom et al. 1996; Pesce et al. 1998a; for review, see Pesce et al. 1998b). In contrast to the immediate down-regulation of *Oct-4* in trophoctodermal and somatic lineages, Oct-4 protein levels are increased initially in cells of another non-germ-line tissue, namely the premigratory hypoblast (Palmieri et al. 1994). Perhaps the initial steps of visceral and parietal endoderm formation depend on increased *Oct-4* expression levels. Proliferation, differentiation, and migration are three processes in which Oct-4 might be involved during formation of these tissues.

Oct-4 is also expressed in undifferentiated embryonal cell lines, each of which represent cells of distinct developmental stages (Schöler et al. 1989a,b; Okamoto et al. 1990). Cultured embryonic stem (ES) and embryonal carcinoma (EC) cells exhibit features peculiar to specific cell types found in early embryos (Robertson 1987). On the basis of biochemical markers, F9 EC cells are a model system for embryonal cells that differentiate by way of a hypoblast-like cell type into visceral or parietal endoderm cells (Strickland and Mahdavi 1978; Strickland et al. 1980; Hogan et al. 1981).

High mobility group (HMG) box proteins are transcription factors that interact functionally with POU domain proteins (Leger et al. 1995; Zwilling et al. 1995; Ambrosetti et al. 1997). *Sox-2* belongs to the *Sox* (*Sry*-related HMG box-containing) gene family and is expressed in preimplantation embryos and in ES and EC cells in a similar manner as *Oct-4* (Yuan et al. 1995; Collignon et al. 1996; R. Lovell-Badge, pers. comm.). Later in development, *Sox-2* is again coexpressed with *Oct-4* in post-migratory primordial germ cells (Collignon et al. 1996). *Sox-2* and Oct-4 are able to act synergistically on reporter genes in transient transfection studies (Yuan et al. 1995). The HMG box DNA-binding domain of *Sry* and other *Sox* proteins induces a strong bend on binding to the DNA (Ferrari et al. 1992; Giese et al. 1992). Thus, the role of *Sry* and *Sry*-related factors may be architectural, facilitating functional protein-protein interactions on enhancers (Ferrari et al. 1992; Giese et al. 1992; Werner et al. 1995).

Understanding the molecular and genetic framework in which Oct-4 operates during the first differentiation processes in development requires identification of its target genes. Several potential target genes of Oct-4 have been proposed (Rosfjord and Rizzino 1994; Kraft et al. 1996; Liu and Roberts 1996; Saijoh et al. 1996). However, the only conclusive candidate gene in early mouse development is *fgf-4* (Schoorlemmer and Kruijer 1991; Daley et al. 1994; Rizzino and Rosfjord 1994). The *fgf-4* gene

has an octamer-containing enhancer downstream of the coding region, which is activated synergistically by Oct-4 and Sox-2 in transient transfection assays (Yuan et al. 1995). Furthermore, *fgf-4* is coexpressed with *Oct-4* and *Sox-2* in the ICM (Niswander and Martin 1992) and in EC and ES cells (Schoorlemmer and Kruijer 1991).

Osteopontin (OPN; also named bone sialo protein I, 2ar, Spp1, Eta-1, and pp69) is especially abundant in bone, kidney, decidua, and various epithelial cells (for review, see Denhardt and Guo 1993; Denhardt et al. 1995). OPN is an extracellular phosphoprotein containing a GRGDS motif. This peptide motif of OPN is capable of mediating adhesion to and migration along the surface of cell types expressing certain classes of integrins (for review, see Eble and Kühn 1997).

In this study we show that *OPN* is a candidate target gene of Oct-4 during the formation of the hypoblast of mouse embryos. EC cells were used as a cell culture model for the biochemical analysis of DNA-protein interactions that occur during hypoblast formation and differentiation. Pools of cross-linked F9 EC chromatin fragments bearing *cis*-acting elements that interact in vivo with Oct-4 were enriched by immunoprecipitation with Oct-4-specific antibodies. PCR analyses showed that the first intron of *OPN* (*i-opn*) was well represented in such a pool in comparison to other regions of *OPN* or to regulatory regions of other genes. The *i-opn* element contained an ES cell-specific enhancer composed of a cluster of high-affinity Oct-4-binding sites and sites for other transcription factors. In vitro, Oct-4 binds to *i-opn* both as a monomer and a dimer, but only the dimer confers transcriptional activation in transfection studies. Enhancer activity of *i-opn* is modulated in F9 EC cells through a Sox-binding site that is in close proximity to the Oct-4-binding sites. Sox-2 in vitro binds to *i-opn* and in cotransfection experiments interferes with Oct-4-mediated activity. This interference depends on a region outside the HMG domain. *Oct-4*, *Sox-2*, and *OPN* are coexpressed in the same cells of the early mouse embryo. In addition, *OPN* up- and down-regulation correlates with the pattern of Oct-4 and Sox-2 expression during differentiation of F9 EC cells. We suggest that genes such as *OPN* are tightly regulated by Oct-4 and Sox-2 in ICM and also in hypoblast cells, which will migrate along the trophoctoderm to become parietal endoderm.

Results

Oct-4 can be isolated as part of the embryonal chromatin

Oct-4 is a transcription factor that binds to the octamer motif ATGCAAAT with high affinity in vitro (for review, see Schöler 1991). Statistically, a haploid mouse genome contains this motif $\sim 4 \times 10^4$ times. Hence, an approach to isolate target genes of Oct-4 on the basis of DNA sequence recognition alone is not feasible because of the high complexity of the mouse genome. One means to narrow down the pool of genes containing octamer motifs to those that may interact with Oct-4 in a physi-

ologically relevant way is by isolating directly DNA sequences to which Oct-4 is bound within the context of a nucleus. The natural arrangement of proteins bound to DNA in the nucleus is preserved by cross-linking before lysis. Subsequent physical fragmentation yields a mixture of covalently linked aggregates of macromolecules that were in proximity of each other within the nucleus. Aggregates containing Oct-4 can be isolated by means of Oct-4-specific antibodies and decross-linked to yield a pool of Oct-4-associated macromolecules, from which DNA fragments can be subcloned. The ideal source of such a chromatin precipitate would be from cells that normally express Oct-4 in the animal. However, Oct-4 is only expressed in the toti- and pluripotent cells of the early mouse embryo. These provide insufficient starting material to perform the type of biochemical isolation outlined above. Hence EC cell lines that resemble cells of the early mouse embryo were used. EC cells express *Oct-4* and can be grown in large enough quantities to perform chromatin precipitation experiments.

A stringent Oct-4 immunoprecipitation procedure for covalently fixed EC cell chromatin was established based on a procedure used to investigate target genes in *Drosophila* (Orlando and Paro 1993). P19 EC cells were labeled with [³⁵S]methionine and fixed with formaldehyde in vivo to preserve native protein-DNA complexes by covalent cross-linking. Covalent bonds formed between endogenous Oct-4 and nearby DNA allows the use of stringent conditions during the subsequent purification of Oct-4-specific chromatin fragments (see Materials and Methods). Cross-linked chromatin was physically fragmented to an average DNA size of 400 bp (Fig. 1C) by an empirically calibrated sonication step and was fractionated on equilibrium cesium chloride (CsCl) gradients. The ³⁵S-label was used to determine protein content of each gradient fraction showing a distribution in two peaks at different CsCl densities (Fig. 1A, top). One peak centered at fraction 15 had a density of ~1.38 gram/cm³, whereas the second was at the top of the gradient (fraction 21). A parallel sedimentation profile of material that had been decross-linked before centrifugation showed only one ³⁵S peak at the top of the gradient, indicating that this material consists of uncross-linked material (Fig. 1B, top). Consequently, the 1.38 gram/cm³ peak was considered as the cross-linked chromatin fraction. Its density is similar to those previously reported for fixed protein-DNA complexes (Solomon et al. 1988).

Immunoprecipitation with an α Oct-4 antibody (α 4) was used to identify Oct-4 in gradient fractions of chromatin fragments decross-linked after or before fractionation. In the gradient of cross-linked chromatin fragments, Oct-4 was detected in the fraction 15 peak but not at the top of the gradient (Fig. 1A, bottom). In contrast, Oct-4 was only detected at the top of the gradient in chromatin that was decross-linked before fractionation (Fig. 1B, bottom). Therefore, Oct-4 was cross-linked efficiently to EC cell chromatin with formaldehyde.

Both proteins and DNA that associate closely with Oct-4 in EC cell chromatin should be cross-linked to

Oct-4 in the procedure described above. Analysis of the cross-linked proteins was investigated to define the specificity of the immunoprecipitation procedure. The set of proteins cross-linked to Oct-4 was ascertained by comparing the profiles of proteins precipitated from the fraction 15 peak by either the α 4 antibody or total antibody from preimmune (PI) serum (Fig. 1D). The α 4 immunoprecipitate (decross-linked just before SDS-PAGE) yielded a large number of proteins with molecular masses >30 kD (Fig. 1D, lane 1). The largest histone (H1) has a size of 22.5 kD, suggesting that these proteins are nonhistone. In addition, the different protein bands may represent associated proteins that bind either directly to Oct-4 or indirectly through DNA. A second precipitation of the decross-linked material with the Oct-4 antibody (Fig. 1D, double IP) gave only one band with the mobility of Oct-4, ruling out the possibility that the high apparent molecular mass of the cross-linked proteins was attributable to incomplete hydrolysis of cross-links. In contrast, PI immunoprecipitates (lane 2) contained no detectable protein, indicating that nonspecific precipitation was extremely low.

The α 4 polyclonal antibody preparation used had been affinity purified by sequential passage over Oct-6- and Oct-4-Sepharose and was without detectable cross-reactivity in a variety of assays (Palmieri et al. 1994; data not shown). However, to ensure that the proteins immunoprecipitated by α 4 from cross-linked chromatin were brought down by virtue of their association with Oct-4, an aliquot of the first α 4 immunoprecipitate was decross-linked and immunoprecipitated again with α 4. As expected, only a single band was detected that had exactly the size expected for Oct-4 (Fig. 1D, lane 3). The α 4 antibody precipitates the same Oct-4 band from P19 EC extracts that were not cross-linked (lane 5). Thus, the α 4 immunoprecipitations of cross-linked chromatin can be used to isolate pools of DNA fragments that lie close to Oct-4 in chromatin in vivo.

Enrichment of OPN in Oct-4 chromatin immunoprecipitates


A second approach used to identify target genes of Oct-4 was to screen the available sequence databases for genes that have octamer motifs together with other *cis*-acting elements that are active in early embryonal cells like Sox-2 recognition sites (Dailey et al. 1994; Yuan et al. 1995). The canonical octamer motif containing one possible A/T variation at position 5 (ATGCA/TAAT) and the Sox-binding site (TCTTTGTT) (Yuan et al. 1995) were used in one search. More than 2000 rodent sequences containing octamer motifs were found in the GenBank-EMBL sequence database. Only 17 of these contained the Sox element within 40 bp of the octamer motif.

Oct-4 levels are increased transiently in the forming hypoblast of the developing blastocyst (Palmieri et al. 1994). Changes in cell adhesion and migration are two hallmarks of the forming hypoblast and occur during blastocyst development as the hypoblast cells delami-

Botquin et al.

Figure 1. Immunoprecipitation of Oct-4-containing chromatin of embryonal cells.

(A) Protein elution profiles of isopycnic CsCl gradients of sheared cross-linked chromatin of P19 EC cells. (B) In parallel to equilibrium ultracentrifugation in CsCl the chromatin that was decross-linked before fractionation. In A and B CsCl density gradients were fractionated and the ^{35}S levels (\square) determined in each fraction. Fraction 1 is bottom of the gradient. The Oct-4 protein elution profile was obtained from aliquots of gradient fractions by hydrolyzing cross-links, and detected by ^{35}S on SDS-PAGE. Lane C contains a control Oct-4 immunoprecipitate of ^{35}S -labeled P19 EC protein extracts. Exposure of the Oct-4 profile in B is three times longer than in A to show that Oct-4 was only detected at the top of the gradient. (C) Cross-linked chromatin was physically fragmented to an average DNA size of 400 bp as determined by an agarose gel stained with ethidium bromide. (D) Immunoprecipitation of cross-linked chromatin with Oct-4-specific antibodies. All immunoprecipitations were performed with aliquots of fraction 15. ^{35}S -Labeled proteins in precipitates were analyzed on 10% SDS-PAGE. (Lane 1) Immunoprecipitation with Oct-4 antibodies ($\alpha 4$); (lane 2) immunoprecipitation with preimmune (PI) antibodies; (lane 3) Oct-4 immunoprecipitated chromatin was hydrolyzed and subjected to a second round of immunoprecipitation with $\alpha 4$ antibodies; (lane 4) reverse cross-linked PI immunoprecipitated chromatin was hydrolyzed and subjected to a second round of immunoprecipitation with PI antibodies; (lane 5) $\alpha 4$ -immunoprecipitates of ^{35}S -labeled P19 EC protein extract. All immunoprecipitations were done with affinity-purified Oct-4 polyclonal antibodies.



nate from the ICM, migrate, and differentiate into visceral and parietal endoderm (Gardner 1983). Of the 17 candidate elements revealed in the sequence search, *OPN* was the only interesting candidate target gene of Oct-4 with respect to adhesion and migration processes in the preimplantation embryo. *OPN* had been proposed to have a role in the adhesion and migration of various vertebrate cell types (Denhardt and Guo 1993; Denhardt et al. 1995). The closely spaced octamer and Sox elements of *OPN* were located in the first intron (i-opn) (Fig. 2A). An engrailed-like (TTAAAAT) sequence, which is also active in early embryonal cells (Okamoto et al. 1990; Fig. 2A), was found in close proximity to the other two elements. An enhancer in the 3' nontranslated region of *fgf-4* also contains these three elements in close proximity (Curatola and Basilico 1990). The combination of Oct-4 and Sox-2 results in cooperative activation of the *fgf-4* enhancer in transient transfection assays (Yuan et al. 1995). Therefore, *fgf-4* is a candidate target gene of Oct-4 and is likely involved in controlling cell proliferation in the early embryo (Schoorlemmer and Kruijer 1991; Dailey et al. 1994; Rizzino and Rosfjord 1994; Feldman et al. 1995).

To determine whether a physiologically relevant interaction takes place between Oct-4 and the i-opn fragment, the relative abundance of this fragment in $\alpha 4$ and PI immunoprecipitates of F9 EC cell chromatin was compared (Fig. 2B). F9 cells were used instead of P19 cells because several studies had indicated that they were more similar to hypoblast cells and could be used to

model hypoblast differentiation in culture (Strickland and Mahdavi 1978; Strickland et al. 1980; Hogan et al. 1981). PCR analysis revealed that the i-opn fragment containing the octamer motifs was clearly present in the $\alpha 4$ chromatin immunoprecipitates, whereas it was not




Figure 2. *OPN* first intron is enriched in EC chromatin α Oct-4 immunoprecipitates. (A) Two elements identified by a computer search for genes containing combination of potential binding sites for Oct-4 (O, boxed) and Sox-2 (S, underlined). An engrailed-like factor-binding site is represented by E, dashed line. Schematic organization of *OPN* gene and localization of the first intron. Solid boxes are coding regions; open boxes are untranslated regions. PORE sequence is represented by inverted arrows. (B) Enrichment of *OPN* first intron in α Oct-4 EC chromatin immunoprecipitates. PCR was performed on F9 chromatin immunoprecipitated with α Oct-4 antibodies ($\alpha 4$) or with preimmune antibodies (PI). PCR on purified F9 genomic DNA (F9) serves as a control for the PCR reactions. Primer pairs were selected to amplify a promoter region of G6PD and exon 7 and intron 1 fragments of *OPN*.

detected in corresponding immunoprecipitates with PI. In contrast, the promoter and exon 7 of *OPN*, and a fragment containing the glucose-6-phosphate-dehydrogenase (G6PDH) promoter were not enriched in either immunoprecipitate but could be detected in F9 genomic DNA (*OPN* promoter not shown). Amplification of the i-opn was verified by cloning and sequencing of the 214-bp band (data not shown). These data indicate that Oct-4 is closely associated with the first intron of *OPN* in the nuclei of undifferentiated F9 EC cells. Enrichment of the enhancer element of *fgf-4* was analyzed in the same pair of immunoprecipitates and revealed that enrichment of the *fgf-4* enhancer element is 8- to 16-fold lower than i-opn (data not shown).

Expression of *OPN* in embryonal cell lines and preimplantation embryos

The close association of Oct-4 with the *OPN* cis-element in the nuclei of cultured cells and the presence of Oct-4-binding sites in this element suggests that Oct-4 regulates physiologically the level of *OPN* transcription. To test this hypothesis, *OPN* and Oct-4 expression levels were compared by Northern blot analysis of poly(A)⁺ RNA from four different embryonal cell lines representing different stages of embryonic development (Fig. 3A; for P19 see Fig. 7A, lane 0, below). MBL-1 ES cells and F9 EC cells resemble cells of the preimplantation embryo, namely ICM and early hypoblast cells, respectively (Strickland and Mahdavi 1978; Strickland et al. 1980; Hogan et al. 1981; Yeom et al. 1996). GCLB cells are derived from P19 EC cells and have many characteristics of early mesodermal cells (Pruitt 1994). All four cell lines express Oct-4 mRNA at similar levels (data not shown). Expression of *OPN* was strongest in F9 EC, intermediate in MBL-1 ES, weak in P19 EC, and not detected in GCLB cells (Figs. 3A and 7A, below). These results show that *OPN* expression varies significantly in Oct-4-positive cell lines. The highest levels are observed in cell lines

resembling the preimplantation embryo, namely in F9 EC and ES, consistent with the idea that Oct-4 up-regulates *OPN* expression in the ICM or hypoblast. 3T3 cells were included in this comparison as a cell line that lacks Oct-4. The expression of *OPN* in the absence of Oct-4 (Fig. 3A) indicates that Oct-4 is not necessary for *OPN* expression in all cell types. It also suggests that the i-opn element bearing the Oct-4-binding sites may only be active during preimplantation development.

Expression of *OPN* was then analyzed in mouse embryos during the morula → blastocyst transition, when Oct-4 is expressed strongly and specifically in the ICM and hypoblast. Oct-4 and *OPN* mRNA levels were estimated by RT-PCR using primer pairs that span introns, thus eliminating the possibility of bands arising from genomic DNA or unspliced hnRNA. Similar levels of Oct-4 mRNA were detected in morulae and 3.5- or 4.5-day blastocysts (Fig. 3B). In contrast, *OPN* mRNA was weakly detected in morulae and became clearly present in the two blastocyst stages. Thus, *Oct-4* expression precedes the onset of *OPN* expression in preimplantation mouse embryos but is unlikely to be sufficient to activate *OPN* expression in morulae.

In situ hybridization experiments were performed to determine whether the expression domains of *OPN* and *Oct-4* overlap in the developing mouse embryo. Embryos of 3.5–6.5 days postcoitum (dpc) were incubated with anti-sense DIG-labeled riboprobes of *OPN* (Fig. 3C). *OPN* was expressed weakly but selectively in the ICM of early blastocysts (Fig. 3C, 3.5 dpc). *OPN* expression was maintained in the ICM and in cells destined to form the hypoblast (Fig. 3C, 4.0 dpc) and was down-regulated in the hypoblast as it formed an epithelial layer of cells (Fig. 3C, 4.5 dpc). Subsequently, expression of *OPN* is also down-regulated in the ICM/epiblast and becomes undetectable in the embryo by 5.5 dpc (Fig. 3C). By 5.5 and 6.5 dpc *OPN* expression was confined to the granulated metrial gland cells (GMGC) in the placenta, which do not express *Oct-4* (Fig. 3C). Expression of *OPN* in the




Figure 3. *OPN* expression in embryonal cell lines and pregastrulation embryos. (A) Northern blot analyses of *OPN* mRNA (*Opn*) expression in F9 EC, GCLB, MBL-1 ES, and fibroblast (3T3) cell lines. Each lane contains 1 µg of poly(A)⁺ RNA. mRNA levels were normalized by comparison of corresponding ethidium bromide-stained 28S and 18S rRNA bands. (B) RT-PCR of *OPN* and Oct-4 mRNA in different stages of preimplantation embryos. Multiplex PCR of Oct-4 and *Opn* was performed on reverse transcripts obtained from F9 cells, morulae (Mo), blastocysts of 3.5 dpc (Bl 3.5) and 4.5 dpc (Bl 4.5). PCR negative controls were done with H₂O (PCR Co) and M2 medium treated with RNA extraction buffers and reverse transcription buffers (M Co). (C) In situ hybridization of 3.5–6.5 dpc embryos with *OPN* DIG-labeled mRNA. Blastocyst staining is observed in ICM and forming hypoblast, but not in trophectoderm and 4.5 dpc hypoblast. In sections of 5.5 and 6.5 dpc embryos only granulated metrial gland cells (GMGC) are stained. (E) embryo. Hybridization with sense probes did not generate staining (not shown).

GMGCs is in agreement with previous results obtained with 7.5-dpc embryos (Nomura et al. 1988; Waterhouse et al. 1992). *OPN* and *Oct-4* expression only overlap in preimplantation embryos, suggesting that this is the physiological time and space at which *OPN* may be a target of Oct-4 control.

Coexpression of *OPN* and *Oct-4* in embryonic cell lines and overlapping expression domains in preimplantation embryos, taken in combination with the enrichment of an Oct-4-binding intron of *OPN* in $\alpha 4$ chromatin immunoprecipitates, clearly suggests a physiological link between the transcription factor Oct-4 and the cell adhesion molecule *OPN*. However, Oct-4 and *OPN* transcript levels do not correlate strictly temporally and quantitatively, suggesting that factors in addition to Oct-4 are involved in the regulation of *OPN* expression during development and in embryonic cell lines.

Oct-4 binds to a 36-bp EC cell-specific enhancer within *i-opn*

Enrichment of *i-opn* in $\alpha 4$ chromatin immunoprecipitates strongly suggests that this piece of DNA provides the interface at which the Oct-4 transcription factor controls *OPN* mRNA levels. The occurrence of a perfect octamer motif (in an inverted dyad configuration with an imperfect octamer motif), a Sox motif, and an engrailed-like motif in a short sequence (+799 to +864 bp) of the *i-opn* fragment (+758 to +1077 bp) further suggests that these sites and the proteins that interact with them provide the combinatorial regulatory complex that governs the expression of *OPN* in preimplantation development. Electrophoretic mobility-shift assays (EMSA) were performed as an initial means to establish which DNA-protein interactions can occur. Bacterially expressed Oct-4 was incubated with an end-labeled fragment of intron 1 (+758 to +1077 bp). Part of the radioactive probe was shifted to a position of lower mobility. Incubation of the mixture with Oct-4-specific antibodies abolished the

low mobility band, demonstrating that Oct-4 can bind to *i-opn* (data not shown; see below).


The *i-opn* fragment was inserted in front of a minimal herpes simplex virus thymidine kinase (HSV *tk*) promoter driving the expression of the luciferase reporter gene to test whether it was active in cells expressing *Oct-4* (Fig. 4A, *i-opn*). Point mutations were introduced into the octamer sequence to measure the contribution of the octamer site to the *i-opn* activity (Fig. 4A, *i-opn* mut). A short *i-opn* region (OS), containing only the Sox, engrailed-like, and octamer-binding sites, was also analyzed for activity (Fig. 4A). The *i-opn*-containing reporter was 4.8 times more active in transiently transfected F9 EC cells than the parental vector without insert (Fig. 4C). Similar activity was obtained with the OS reporter (Fig. 4C). In contrast, the reporter bearing a mutated *i-opn* (*i-opn* mut) lacked detectable activity (Fig. 4C). Therefore, *i-opn* contains *cis*-acting elements, in particular the octamer site, that confer expression in F9 EC cells.

To assess the activity of the octamer motif in *i-opn*, short fragments containing the octamer dyad and engrailed-like motif (Fig. 5B, O oligonucleotide; positions +827 to +863) were oligomerized and tested in transactivation assays. Six and 10 direct repeats of the O oligonucleotide were inserted into the *tk* luciferase reporter plasmid (Fig. 4A). Expression of these reporters was compared to the parental reporter by transient transfection assays. Reporters bearing O repeats showed significantly higher levels of luciferase activity than parental reporters in F9 EC but not in 3T3 cells (Fig. 4D). These results demonstrate that a 36-bp-long region within *i-opn* can confer EC cell-type specificity when multimerized and suggests that this element provides the interface at which Oct-4 acts to regulate *OPN* during preimplantation development.

Oct-4 binds as a monomer and dimer to the O element

The interaction of Oct-4 and other POU domain tran-

Figure 4. *OPN* first intron functions as an EC-specific enhancer. (A) Reporter constructs. HSV *tk* minimal promoter cloned upstream of the luciferase gene (Luc); *i-opn* and *i-opn* mut are PCR fragments of the *OPN* first intron from +758 to +1077 wild-type and point mutated octamer motif, respectively; OS denotes *OPN* first intron from +796 to +863. 6 × O and 10 × O denote 6 or 10 copies of the O oligonucleotide, respectively. All fragments were cloned upstream of -37 *tk* luc. (B) Oligonucleotide O represents a short fragment of *i-opn* that binds to Oct-4. The octamer motif is boxed and the PORE is represented by two inverted arrows. (C, D) F9 (solid bars) and 3T3 (open bars) cells were transfected transiently with 10 μ g of respective reporter and 2 μ g of human β -actin-LacZ used as an internal standard to normalize luciferase activity. Fold activation refers to the quotient of luciferase activities in the test and control (*tk* luc) construct.



New Oct-4 dimerization in OPN preimplantation enhancer




Figure 5. Oct-4 binding to and transactivation by the PORE (A) EMSA demonstrating Oct-4 homo- and heterodimerization on a PORE-containing oligonucleotide (O). (Lane 1) F9 cell extracts; (lane 2) F9 cell extracts incubated with Oct-4 antibodies; (lane 3) F9 cell extracts incubated with Oct-1 antibodies; (lane 4) COS extract containing an Oct-4 protein lacking 98 amino acids at the amino terminus; (lane 5) F9 EC cell extract; (lane 6) mixture of extracts used in lanes 4 and 5; (lane 7) mixture of purified recombinant Oct-4 and Oct-6; (lane 8) recombinant Oct-4; (lane 9) recombinant Oct-6. (B) EMSA of recombinant Oct-4 (rOct-4) and F9 extracts (F9) with the O oligonucleotide and mutated versions thereof (see O⁻¹, O⁻², O⁻³, O⁻⁴, P⁻¹, and P⁺¹ in C). (P) Free probe. Complexes in A and B are as follows: (1) Oct-1 monomer; (4) Oct-4 monomer; the complexes labeled 4a and 4b correspond to Oct-4 monomer in mobility and are considered to represent two differentially phosphorylated forms of Oct-4 (V. Botquin, unpubl.). These bands are not clearly resolved in lanes 1 and 3 of A, lane O with F9 extracts of B and therefore, are merely labeled 4. (1/*) Oct-1 homo- or heterodimer; (4/4) Oct-4 homodimer; (Δ 4/ Δ 4) homodimer of truncated

Oct-4; (4/ Δ 4) heterodimer of full-length and truncated Oct-4; (6/6) Oct-6 homodimer; (4/1) heterodimer of Oct-4 and Oct-1; (4/6) heterodimer of Oct-4 and Oct-6. (C) Specific point and phasing mutations in O oligonucleotide to analyze binding and transactivation requirements in B and D. Point mutations were introduced at base pairs predicted to make central contacts with the POU_S domain (O⁻¹), the POU_{HD} (O⁻³, O⁻⁴), or both (O⁻²). Oligonucleotides capable of binding Oct-4 as a dimer or a monomer are denoted by D⁺ and M⁺, respectively. (N) Number of nucleotides between the two half sites of the PORE. The octamer motif is boxed and the PORE is labeled by two inverted arrows. Dots represent nucleotides identical to those in oligonucleotide O. (D) Transactivation by mutated versions of oligonucleotide O. 6 × O, 6 × O⁻¹, 6 × O⁻², 6 × O⁻³, and 6 × O⁻⁴ are six copies of O, O⁻¹, O⁻², O⁻³, and O⁻⁴, respectively, inserted upstream of *tkluc*. All constructs contain a TATA box at similar distances from the insert. F9 EC cells were transfected transiently with 10 μ g of respective reporter and 2 μ g of human β -actin LacZ, which served as an internal standard to normalize luciferase activities for transfection efficiency. Fold activation refers to the quotient of luciferase activities in test and control (*tkluc*) constructs.

scription factors with the octamer motif, and various synthetic derivatives thereof, has been studied extensively (for review, see Schöler 1991; Verrijzer and van der Vliet 1993; Herr and Cleary 1995; Ryan and Rosenfeld 1997). However, few studies have examined this interaction using octamer motifs embedded in naturally occurring sequence contexts, using physiologically relevant cell extracts. Therefore, the O oligonucleotide was tested in an EMSA for binding with proteins from F9 EC cell extracts (Fig. 5A). Three of the five complexes observed contained Oct-4 because they were removed by addition of Oct-4-specific antibodies (Fig. 5A, cf. lanes 1 and 2). The complex labeled 4/4 corresponds to a dimer of Oct-4 bound to the O oligonucleotide (see below). A third band, labeled 4/1, was composed of Oct-4 and Oct-1 because it was abolished by both Oct-1 and Oct-4 antibodies (lanes 2,3). In addition, two other Oct-1 complexes, labeled 1 and 1/*, were recognized by Oct-1 antibodies (lane 3).

Oct-4-containing complexes were further investigated by using purified recombinant Oct-4 (rOct-4). Bacterially expressed Oct-4 generated two complexes when incubated with the O oligonucleotide (complexes 4 and 4/4; Fig. 5B, lane O, left and right). Both have similar mobili-

ties as Oct-4 complexes obtained with F9 EC cell extracts, suggesting that in EC cells these complexes contained only Oct-4 (Fig. 5B, cf. lanes O in rOct-4 and F9).

To determine the number of Oct-4 molecules within these complexes, two extracts containing Oct-4 proteins of different size were mixed before EMSA (Fig. 5A, lane 6). The shorter version of Oct-4 was expressed in COS cells (Fig. 5A, lane 4, complex labeled Δ 4) and lacks 98 amino acids at the amino terminus (16Oct-4; Schöler et al. 1990b). The longer version of Oct-4 was the complete protein from F9 EC cells (Fig. 5A, lane 5, complex labeled 4a/4b). The truncated Oct-4 protein formed two bands (Δ 4 and Δ 4/ Δ 4), each with higher mobility than corresponding bands with the complete protein (4a,4b and 4/4; Fig. 5A, cf. lanes 4 and 5). Nontransfected COS cells did not give rise to these complexes, indicating that these complexes contained Oct-4 protein (data not shown). Mixed extracts (Fig. 5A, lane 6) containing both Oct-4 versions gave a set bands that was a composite of the two individual extracts. However, in addition, a complex of intermediate mobility was observed between 4/4 and Δ 4/ Δ 4, which was composed most likely of one short and one long version of Oct-4 (4/ Δ 4). Thus,

Botquin et al.

Oct-4 can bind to the O fragment of *i-opn* as a monomer, a homodimer, or, together with Oct-1, as a heterodimer.

To further investigate the ability of Oct-4 to heterodimerize with other POU factors, EMSA was performed using a mixture of purified Oct-4 and rOct-6 (Fig. 5A, lanes 7–9). Similarly to Oct-4, Oct-6 formed monomer and homodimer complexes on the O oligonucleotide (complexes 6 and 6/6; lanes 8,9). In addition to the set of complexes obtained by individual Oct-4 and Oct-6 proteins, an additional band 4/6 of intermediate mobility between 4/4 and 6/6 was observed after mixing both proteins together (Fig. 5A, lane 7). This shows that Oct-4 can heterodimerize with both Oct-6 and Oct-1.

Oct-4 dimer formation requires the palindromic sequence ATTTG N₅ CAAAT.

The O fragment contains the canonical octamer motif ATGCAAAT that is bound by several POU proteins. POU_S binds to the first and POU_{HD} to the second half of this motif (Klemm et al. 1994). An inverted CAAAT sequence is located 5 nucleotides upstream of the CAAAT in the octamer motif (Fig. 5C). This dyad sequence motif was likely to be required for the formation of Oct-4 dimer complexes. Point mutations were introduced at various positions within the O oligonucleotide to determine which residues were required for Oct-4 monomer and dimer formation. The mutagenesis strategy was designed to reduce specifically binding of either POU_S (O⁻¹) or POU_{HD} (O⁻³, O⁻⁴) of Oct-4, or both (O⁻²) (Fig. 5C, dimer–monomer-binding site mutations). This was performed by altering critical residues of the dyad motif that are predicted, based on the known crystal structure of a POU domain–DNA complex, to make contacts with these two subdomains (Klemm et al. 1994). Mutated oligonucleotides were incubated with either bacterially expressed Oct-4 (rOct-4) or F9 EC cell extracts and analyzed by EMSA (Fig. 5B, left).

rOct-4 binds as a monomer and a dimer to the wild-type oligonucleotide (Fig. 5B, lane O). When a mutation in the first half of the octamer motif was introduced, only rOct-4 monomer formation was affected (lane O⁻¹). In contrast, dimerization of rOct-4 was abolished specifically by a mutation in the ATTTG (inverted CAAAT) sequence located 5' to the octamer motif (lane O⁻³). When both mutations were combined neither dimer nor monomer were detected (lane O⁻²).

A point mutation was introduced into the second half of the octamer motif to test whether the right half site of the palindromic sequence is also required for dimer formation (lane O⁻⁴). Indeed, dimer formation on this oligonucleotide was abolished and binding of the monomer was reduced drastically. The mobility of the monomer complex was also slightly increased in comparison to that formed on the wild-type sequence, possibly as a result of a different binding mode. One likely explanation is that the homeodomain now can only bind to the left half site of the palindrome (inverted CAAAT). An altered binding conformation could result in different DNA

bending and, as a consequence, in altered mobility of the complex (Verrijzer et al. 1991).

Oligonucleotides with one nucleotide inserted or deleted between the palindromic motifs were also tested with rOct-4 for dimer formation (Fig. 5C, phasing mutations). In neither case was the dimer complex formed, indicating dimerization is highly dependent on proper spacing of the two Oct-4 molecules bound to the palindrome (Fig. 5B, right). The phasing mutations also abolished the formation of Oct-4 homo- and Oct-4/Oct-1 heterodimers in F9 EC cell extracts (data not shown). The specific amino acid side chains required for dimer formation have to be determined.

Oct-4 of F9 EC cell extracts and rOct-4 basically gave the same pattern of complexes with all oligonucleotides (Fig. 5B, cf. left and right). However, dimer formation with rOct-4 was far more efficient than with F9 Oct-4 (cf. both O lanes). In addition, the mutation (O⁻¹) that abolished monomer formation and increased dimer formation with rOct-4 (two- to threefold; compare O and O⁻¹ lanes), reduced monomer but did not increase dimer formation in F9 EC extracts. These results suggest that Oct-4 in F9 EC extracts is modified in a way that interferes with dimerization.

The mutagenesis assays presented above indicate that formation of the monomer complex requires an intact POU_S half site and at least one intact POU_{HD} half site. The POU_{HD} half site of the octamer motif results in a more stable monomer complex than the inverted half-site found upstream. In contrast, formation of the Oct-4 dimer complex on the O fragment requires two intact POU_{HD} half sites but does not require an intact POU_S half site. Dimerization of Oct-4 depends on the palindromic motif ATTTG–CAAAT, which has to be spaced by five nucleotides. This motif will be subsequently called PORE, for palindromic Oct recognition element.

PORE mediates function of the EC cell enhancer

To determine whether monomer or dimer complexes were mediating the EC cell-specific enhancer function of *i-opn*, mutagenized oligonucleotides were multimerized and inserted at position –37 in the standard *tk* luciferase reporter plasmid. The reporter activity of each mutant O-multimer was compared to the activity generated by the wild-type O-multimer (6 × O) in transient transfections in F9 EC cells (Fig. 5D). Hexamers of the O⁻¹ fragment, which only binds Oct-4 as a dimer (Fig. 5B, left), activated the reporter in a manner similar to the hexamer of the wild-type sequence (Fig. 5D, cf. 6 × O with 6 × O⁻¹). In contrast, a hexamer of the O⁻³ fragment, to which Oct-4 bound only as a monomer, activated transcription only two- to threefold (6 × O⁻³). This was only slightly above the level of activation by hexamers of O⁻², to which Oct-4 could not bind at all (6 × O⁻²). These results demonstrate that the PORE and not the octamer motif activates transcription of the reporter gene efficiently. They suggest that the PORE is also important for the function of the EC-cell-specific enhancer found in *i-opn*. The in vitro binding data sug-

gest that PORE activity in vivo depends on Oct-4 homo- or heterodimerization with either Oct-1 or Oct-6.

Sox-2 interferes with Oct-4-mediated transcriptional activation

The variation in *OPN* expression levels in different ES and EC cell lines (see Fig. 3A) may be attributable to differences in Oct-4 dimerization or binding of other regulatory factors. However, Oct-4 mRNA and protein levels do not vary in the ES and EC cell lines examined so far. In addition, monomer binding is similar in all extracts of these cell types (Yeom et al. 1996; data not shown). As an initial test to determine whether *OPN* expression is modulated by different dimer levels, in vitro dimer formation was compared in different embryonic cellular extracts (Fig. 6A, left). Oct-4 dimer formation was very similar in all cell extracts and thus cannot explain why *OPN* levels vary in the ES and EC cells. However, we observed an inverse correlation between *OPN* expression and the presence of the 4/1 and 1/* complexes, suggesting that an Oct-4/Oct-1 dimer could repress the activity of the i-opn enhancer.

Sox-2 is another candidate transcription factor that

could modulate Oct-4-mediated activity of i-opn. The Sox-binding site was used in our initial computer analysis to restrict the number of potential Oct-4 target genes (see Fig. 2A). Oct-4 and Sox-2 proteins increase transcription synergistically from the *fgf-4* enhancer activity (Yuan et al. 1995). An oligonucleotide spanning the i-opn region with the canonical Sox-binding site (S oligonucleotide) was used to test for differences in Sox-2-binding activity in ES and EC cell lines (Fig. 6A, right). One major complex was formed in F9, P19, and ES cells. A common test for Sox-factor binding is the competition by poly[d(I-C)] (Dailey et al. 1994). Incubation of the reaction mixture with poly[d(I-C)] instead of poly[d(G-C)] resulted in a specific competition of the Sox-2 complex [Fig. 6A, lanes ES(IC) and F9 EC(IC)]. In addition, point mutations within the Sox motif decreased formation of this complex (data not shown; see below). Finally, in both F9 EC and ES extracts, Sox-2 binding was affected specifically by Sox-2 antibodies [Fig. 6A, lanes ES(α 2) and F9 EC(α 2)]. The Sox-2 complex varies in extracts of the different cell types. The strongest signal was obtained with ES cell extracts, a weaker band with F9 EC and P19 EC (Fig. 6A, right). Finally, no Sox-2 complex could be detected in GCLB and 3T3 (Fig. 6A, right).




Figure 6. Sox-2 binds i-opn and represses Oct-4-mediated transactivation. (A) EMSA of EC cell (P19 and F9), ES cell, GCLB, and fibroblast (3T3) cell extracts on O and S oligonucleotides. Sox-2 binding was affected with either poly[d(I-C)] (IC) or Sox-2 antibody (α 2). Complexes are as follows: (4/4) Oct-4 monomer; (4/1) Oct-4 homodimer; (4/1) heterodimer of Oct-1 and Oct-4; (1) Oct-1 monomer; (1/*) Oct-1 homo- or heterodimer; (PIO-1) protein binding to *intron 1* of *osteopontin*. (B,C) Transient transfection assays in F9 EC and ES cells with reporters carrying octamer and Sox-binding sites. 6 \times O represents a hexamer of oligonucleotide O (PORE only), 6 \times OS a hexamer of OS (PORE and Sox-binding sites), 6 \times O⁻S a hexamer of O⁻S (mutated PORE, intact Sox-2-binding site), 6 \times OS_a⁻ and 6 \times OS_b⁻ hexamers of OS_a⁻ and OS_b⁻, respectively (intact PORE, mutated Sox-binding site). All hexamers were cloned upstream of *tkluc*. F9 EC and ES cells were transfected transiently with 10 μ g of respective reporter and 2 μ g of human β -actin-LacZ as an internal standard. Fold activation refers to the quotient of luciferase activities in test and control (6 \times O) constructs.

(D) Cotransfection assay in 293 cells of 1 μ g of 6 \times OS reporter and increasing amount of CMV Oct-4 effector. (E) Cotransfection assay in 293 cells of 1 μ g of 6 \times OS reporter, constant amount of CMV Oct-4 and increasing amounts of CMV Sox-2 effector. (F) Cotransfection assay in 293 cells of 1 μ g of 6 \times OS reporter, constant amount of CMV Oct-4 and increasing amount of CMV NP2 effector. (G) Cotransfection assay in 293 cells of 1 μ g of 6 \times OS_a⁻ reporter and increasing amount of CMV Oct-4 effector. (H) Cotransfection assay in 293 cells of 1 μ g of 6 \times OS_a⁻ reporter, constant amount of CMV Oct-4 and increasing amounts of CMV Sox-2 effector. All luciferase activities were normalized for β -galactosidase expression. Light units refers to the units of luciferase counts.

Botquin et al.

A novel low mobility complex [PIO-1 (proteins binding to intron 1 of osteopontin)] formed on the S oligonucleotide when P19 EC and GCLB cell extracts were used (Fig. 6A). The identities of proteins in PIO-1 are unclear. PIO-1 is unlikely to contain Sox-2 because it was not affected by Sox-2 antibodies [Fig. 6A, right, GCLB ($\alpha 2$)]. Sox-2 and PIO-1 binding is found predominantly in ES and EC cells in which *OPN* expression is low or undetectable, namely in ES, P19 EC, and GCLB. Thus, the presence of the Sox-2 and PIO-1 can be correlated with the expression pattern of *OPN* in cell lines corresponding to different embryonic cell types.

The activity of the Sox-2-binding site was analyzed in transient transfection assays. The hexamer of the S oligonucleotide in front of the *tk* luciferase reporter was inactive in F9 EC cells, confirming previous results that a Sox-2-binding site by itself cannot activate transcription (data not shown, Yuan et al. 1996). To study the functional interaction of Sox-2 and Oct-4, longer oligonucleotides spanning both the Oct and the Sox motifs (termed OS) were oligomerized and cloned in front of the standard reporter (position +798 to +863). Tandem hexamers of the native sequence ($6 \times OS$) were inserted upstream of the *tk* luciferase reporter and compared to tandem hexamers of mutated versions. Mutations were either in the octamer motif ($6 \times O^-S$) or in the Sox-binding site ($6 \times OS_a^-$; complete replacement; $6 \times OS_b^-$; point mutated site). In vitro binding analyses indicated that Sox-2 binding to OS_a^- and OS_b^- was undetectable or weak, respectively (not shown). Reporter constructs were transfected into F9 EC cells and their activity was analyzed (Fig. 6B). The wild-type hexamer $6 \times OS$ was twice as active as the shorter $6 \times O$ fragment. The activity of $6 \times OS$ depended on intact Oct factor-binding sites, because the mutated counterpart ($6 \times O^-S$) was inactive. Strikingly, mutations of the Sox-binding site ($6 \times OS_a^-$ and $6 \times OS_b^-$) resulted in an additional 9.5- to 10-fold activation (Fig. 6B, cf. $6 \times OS$ with $6 \times OS_a^-$ and $6 \times OS_b^-$). These results indicate that the Sox-binding site is a negative element that interferes with the activity of other elements within the OS fragment, most likely with the activity of the Oct-4-binding sites.

Sox-2-binding intensity differs in ES and in F9 EC cell extracts (Fig. 6A, right). We compared the activity of the wild-type hexamer $6 \times OS$ in these two cell types (Fig. 6C). The $6 \times OS$ reporter was twice more active in F9 EC compared to ES cells and thus the OS activity correlated inversely with Sox-2-binding intensity. In addition, mutation of the Sox-binding site ($6 \times OS_a^-$) resulted in an additional 20-fold activation in ES compared to a fivefold activation in F9 EC cells (Fig. 6C). This suggests that Sox-2 may decrease the level of *OPN* expression in ES cells. PIO-1 may act as another negative factor involved in a down-regulation of *OPN* in GCLB and P19 EC cells (Fig. 6A, right).

To assess directly the effect of Sox-2 on Oct-4, both factors were cloned into CMV vectors and expressed in 293 cells. First, increasing amounts of the Oct-4 expression vector was cotransfected with a constant amount of the $6 \times OS$ reporter (Fig. 6D). Reporter activity was in-

creased in direct proportion with the amount of the expression vector added. The highest amount (1 μ g) tested in this experiment stimulated the reporter >20-fold. Subsequently, increasing amounts of the Sox-2 expression vector was cotransfected with a constant amount of both the Oct-4 expression and the $6 \times OS$ reporter vectors. In this case, increased amounts of Sox-2 expression vector steadily decreased the activity mediated by Oct-4 (Fig. 6E). This negative effect depended on an intact Sox element because even the highest amount of Sox-2 did not interfere with Oct-4-stimulated activity of $6 \times OS_a^-$ reporter (Fig. 6G,H). These results indicate that Sox-2 can reduce levels of Oct-4-mediated transactivation from the $6 \times OS$ reporter and that binding of Sox-2 protein to the canonical Sox motif is required for its repressive effect.

A transactivation domain has been mapped to the carboxy-terminal portion of Sox-2 (Yuan et al. 1995). To determine its contribution to the repressive effect of Sox-2, a truncated version lacking this region was cotransfected with a constant amount of both $6 \times OS$ reporter and Oct-4 expression vectors. Increasing amounts of the truncated Sox-2 protein (NP2) stimulated the reporter up to threefold (Fig. 6F). This activation by NP2 is in striking contrast to the decrease mediated by the complete protein and might indicate an architectural modification of the chromatin-facilitating Oct-4 interaction with the basal transcriptional machinery. The result suggests that transcriptional repression by Sox-2 is not likely attributable to competitive binding of Sox-2 with another transcription factor, rather it is the result of the carboxy-terminal region of Sox-2 that interferes with Oct-4-mediated transcriptional activation.

Oct-4, Sox-2, and OPN expression correlate during hypoblast differentiation

The ICM of the blastocyst, which coexpresses *Oct-4*, *Sox-2*, and *OPN*, differentiates into the epiblast and hypoblast (Gardner 1983; Palmieri et al. 1994; R. Lovell-Badge, pers. comm.; see Fig. 3C). The hypoblast is localized initially to the blastocoelic surface of the ICM and gradually spreads over the inner surface of the blastocoel as it differentiates into parietal and visceral endoderm (Gardner 1983). Oct-4 protein levels increase in cells that form the hypoblast, but decrease drastically as the hypoblast differentiates further (Palmieri et al. 1994). In contrast, *Sox-2* expression is down-regulated immediately in cells of the hypoblast lineage (R. Lovell-Badge, pers. comm.).

F9 EC cells are often used as a cellular model to study hypoblast-specific questions (Strickland and Mahdavi 1978; Strickland et al. 1980; Hogan et al. 1981). In a first attempt to compare *Oct-4* and *OPN* expression levels during this specific stage, F9 EC cells were induced to differentiate into parietal and visceral endoderm (Fig. 7A, nonaggregates and aggregates, respectively). In both differentiation modes F9 EC cells are considered to initially pass through a hypoblast-like stage (Adamson 1986). Undifferentiated F9 EC cells expressed moderate levels of *Oct-4* and *OPN* (Fig. 7A, F9 lane 0 in each panel). A

New Oct-4 dimerization in OPN preimplantation enhancer




Figure 7. Correlation of *OPN*, *Oct-4*, and *Sox-2* expression during F9 and P19 differentiation. (A) F9 EC cells were induced to differentiate into parietal endoderm by exposing adherent cells to 10^{-1} μ M all-*trans* retinoic acid (RA) (nonaggregates) or into visceral endoderm by exposing cells grown in suspension to 10^{-1} μ M RA (aggregates). P19 were treated with 1 μ M all-*trans* RA. Total RNA was extracted at day 0 (untreated F9 and P19 cells), day 1 and 2 of RA treatment. Northern blot analyses were performed for *OPN*, *Oct-4*, and *28S rRNA* probes. Each lane contains 10 and 30 μ g of total mRNA in F9 and P19 EC cells, respectively. The same filter was sequentially hybridized to *OPN*, *Oct-4*, and *28S rRNA* probes. (B) EMSA of differentiating F9 and P19 EC cell extracts. Whole cell extracts at day 0 (untreated F9 and P19 EC cells), day 1 and 2 of RA treatment were incubated with the O and S oligonucleotide used as probe. Complexes are denoted as follows: (4) Oct-4 monomer; (4/4) Oct-4 homodimer; (4/1) heterodimer of Oct-1 and Oct-4; (1) Oct-1 monomer; (1/*) Oct-1 homo- or heterodimer. PIO-1 complex in P19 EC cells could be observed only after longer exposure.

transient 2.5-fold increase in both *Oct-4* and *OPN* mRNA levels was observed after 1 day of retinoic acid (RA) treatment regardless whether F9 EC cells were differentiating along visceral or parietal pathways (Fig. 7A, F9 lane 1 in each panel). *Oct-4* and *OPN* mRNA levels decreased to undetectable levels after 2 days in RA (Fig. 7A, F9 lane 2 in each panel). Induction of laminin expression, used as a marker for parietal and visceral endoderm, was observed after 1 day of differentiation of F9 EC cells (data not shown). These results demonstrate a strict correlation between *Oct-4* and *OPN* expression during differentiation of F9 EC. The profile of *Oct-4* mRNA up- and down-regulation is closely followed by *OPN* mRNA levels and recapitulates up- and down-regulation of these genes observed during the hypoblast formation.

Oct-4 and *OPN* expression was also compared in RA-treated P19 EC cells, which were induced to differentiate along a neuronal pathway (Robertson 1987). In contrast to F9 EC cells, the level of *Oct-4* and *OPN* transcripts were down-regulated immediately (Fig. 7A, P19). Therefore, the transient increase of *OPN* mRNA during F9 EC cell differentiation is not likely attributable to a direct effect of RA on *OPN* gene regulation.

The in vitro binding activities of *Oct-4* and *Sox-2* were compared with the *OPN* transcript levels during differentiation of F9 EC and P19 EC cells (Fig. 7B) to determine whether a correlation between factor binding and *OPN* expression could be established. *Oct-4* monomer and dimer binding to the O oligonucleotide encoding the i-opn site was not noticeably altered in F9 extracts prepared after 1 day of differentiation (Fig. 7B, right: F9, cf. lane 0 with lane 1). Extracts prepared after 2 days of differentiation showed similar monomer binding but had a marked reduction in *Oct-4* dimer formation (Fig. 7B, left: F9, lane 2). In contrast, the level of *Sox-2* decreased immediately after 1 day of differentiation (Fig. 7B, right: F9, lane 1) and only low levels of *Sox-2* were detected after 2 days of RA treatment (Fig. 7B, right: F9, lane 2). These results suggest that transiently elevated *OPN* expression levels observed after 1 day of RA treatment may be attributable to the more rapid decline in *Sox-2* binding than in *Oct-4* binding. Consequently, the inhibitory action of *Sox-2* on *Oct-4* in the i-opn fragment (above) is alleviated temporarily, resulting in higher levels of i-opn activity in the brief interval before both factors are absent.

The level of *Oct-4* in P19 cells decreased to undetectable levels after 2 days of differentiation (Fig. 7B, left: P19). An additional complex detected at day 1 of RA treatment (Fig. 7B, left: P19, lane 1, mobility between 4 and 4/4 complex) may contain *Brn-2* (Fujii and Hamada 1993). In contrast to *Oct-4*, only a slight decline of *Sox-2* levels was observed after 2 days of differentiation (Fig. 7B, left: P19), suggesting that the rapid decrease of *Oct-4* protein levels might result in an immediate *OPN* down-regulation.

Discussion

In this study we show that *OPN* is likely a direct target gene of *Oct-4* in cells of the mouse preimplantation embryo. *Oct-4* is thought to play an important role in the establishment of hypoblast-derived cell layers (Palmieri et al. 1994) and *OPN* is a secreted phosphoprotein containing a RGD motif promoting adhesion and migration in various cell types (for review, see Denhardt and Guo 1993; Denhardt et al. 1995). We have demonstrated that *Oct-4* is found in close association to a new EC-cell-specific enhancer of the *OPN* gene, i-opn, in the chromatin of EC cells. Furthermore, the activity of the i-opn enhancer in these cells depends on at least two transcription factors that are coexpressed in the preimplantation embryo, namely *Oct-4* and *Sox-2* (Rosner et al. 1990; Schöler et al. 1990b; R. Lovell-Badge, pers. comm.). *Oct-4* binds as a dimer to a specific element, termed PORE, in

Botquin et al.

the *i*-opn enhancer, and transactivates more strongly from this element than from the canonical octamer motif alone. Biochemical analysis of POU protein binding to mutated PORE elements indicates that the Oct-4/PORE complex provides a new paradigm for the interaction of POU proteins with DNA by using only the homeodomain core motifs for binding. Sox-2 also binds to the *i*-opn enhancer and represses transactivation by Oct-4 and other as yet unidentified factors. Sox-2-mediated repression in *i*-opn contrasts with Sox-2-mediated activation in the *fgf-4* enhancer (Yuan et al. 1995). Sox-2-mediated repression and activation of Oct-4 function in these two enhancers depends on the carboxy-terminal region of Sox-2 (Yuan et al. 1995).

Oct-4 dimer formation on the PORE

The POU transcription factors contain a pair of closely and flexibly linked DNA-binding domains that, in principle, have numerous possible modes of interactions with substrate DNA. The POU_S and POU_{HD} domains can be separated and bind DNA independently. However, mixing experiments demonstrate that the separated domains, as well as the linked domains, can bind cooperatively to appropriate DNA substrates (Klemm and Pabo 1996). Analysis of crystals containing POU protein–DNA complexes has revealed that the amino-terminal POU_S domain is joined to the POU_{HD} domain by an unstructured linker that would allow each domain to dock onto DNA with few steric constraints imposed by the other domain (Klemm et al. 1994). The linker of Oct-4 is relatively short (17 amino acids) compared to those of other POU proteins (15–56 amino acids) and constrains the distance between and the relative orientation of two half sites for simultaneous binding. The crystal structure of the Oct-1 POU domain bound to the octamer sequence of the histone H2B promoter (Klemm et al. 1994) shows that the POU_S domain interacts with the 5' ATGC portion of the octamer motif and the POU_{HD} with the 3' A/T-rich portion. The two domains bind to opposite faces of the DNA helix and contact the same base pairs at the center of the octamer motif, but do not interact directly. The fact that POU_S and POU_{HD} bind the same base pairs, albeit at opposite sides, has been suggested to be important for mediating cooperative binding of POU_S and POU_{HD} through changes in the DNA structure (Klemm and Pabo 1996). According to the length and the conformational flexibility of the linker, it seems possible that binding of two more distantly spaced half sites by the two domains of a POU protein monomer occurs.

A second possibility is that the linker allows the POU protein to bind half sites in different orientations. This is demonstrated by the crystal structure of the Pit-1 POU domain on a palindromic recognition site (ATG-TATATACAT; Jacobson et al. 1997). Although the protein folds of each of the two Pit-1 DNA-binding domains, and the docking onto DNA of each domain is very similar to that observed in the Oct-1 crystal, the relative orientation of the two domains in the two crystals is

inverted. The Oct-1 POU_S domain recognizes the GCAT half-site and the Pit-1 POU_S domain binds a corresponding sequence GTAT. However, the latter motif lies on the opposite strand (schema in Fig. 8D). As a consequence, the orientation of POU_S relative to POU_{HD} is inverted.

Cooperative binding by domains of two different POU protein molecules provides a second fundamentally different mode of POU protein–DNA interaction. In the Pit-1 crystal, the repeat unit is a homodimer in which a dimerization interface is formed between the amino-terminal part of POU_{HD} helix 3 of one Pit-1 molecule and the amino-terminal end of POU_S in the second molecule (helix 1 in conjunction with the loop between helices 3 and 4).

Our data show that *in vitro* Oct-4 also forms a homodimer on DNA. However, mutagenic analysis of the binding site (Fig. 5A,B) and computer modeling suggest that the Oct-4 dimer is different than the Pit-1 dimer (schema on Fig. 8D) and illustrates yet a third means by which POU proteins can interact with specific DNA sequences. In contrast to Pit-1, which requires the palindromic arrangement of ATGTAT without any spacing, the Oct-4 dimer requires a palindrome of ATTTG with an exact spacing of 5 nucleotides (Figs. 5B and 8D). The second half site of the PORE is contained in the octamer motif, but specific binding of POU_S to the ATGC sequence seems not to be required as shown by a mutational analysis (Fig. 5B,C). To determine the arrangement of both Oct-4 POU domains the sequence of Oct-4 POU domain was modeled into the coordinates of Oct-1 POU domain (Fig. 8A,B). Because the POU domains of Oct-1 and Oct-4 are extremely well conserved, it is likely that Oct-4 POU domain protein structure bound to DNA is similar to that of Oct-1 (Herr and Cleary 1995; Fig. 8C). This was done first for the octamer motif that overlaps with the second half site of the PORE and then extended to the other half site (Fig. 8A). The arrangement basically results from a point-symmetrical flipping of the first Oct-4 POU molecule with respect to the second. In case of Oct-4, the amino terminus of POU_{HD} (nonhelical region between linker and helix 1) would interact with the carboxy-terminal part of POU_S helix 1 and the loop between helices 1 and 2. Thus, dimerization of Oct-4 on the PORE likely represents a new paradigm for POU protein–DNA interaction.

According to this model, several side chains are predicted to interact with each other. The computer model of Oct-4 POU domain binding to the PORE predicts that Ile-21 of the POU_S domain of one molecule is within 4 Å of Ser-7 of the POU_{HD} of the other molecule (Fig. 8C, numbering of the POU domain according to Herr and Cleary 1995). Thus, the molecules would be in very close proximity at one position on each side of the dimer. Phosphorylation of Ser-7 in the Oct-1 POU_{HD} inhibits binding to the octamer sequence in the H2B promoter (Segil et al. 1991). DNA binding is also reduced in case of Thr-7 phosphorylation of the Pit-1 POU_{HD}, but the magnitude of the effect is dependent on the DNA sequence (Kapiloff et al. 1991; Caelles et al. 1995). Both Ser and




Figure 8. Computer modeling of Oct-4 POU domain dimer conformation on the PORE binding sequence. (A,B) Lateral and frontal view of Oct-4 POU domain dimer conformation on the PORE binding site. Oct-4 POU domains were modeled into the coordinates of Oct-1. Each Oct-4 molecule has one color. The POU_S domain has four α -helices (labeled 1–4) and the POU_{HD} has three α -helices (labeled 1–3). DNA structure is represented by purple for phosphate, red for oxygen, green for carbon, and blue for nitrogen. A and B generated with WHAT IF software. (C) Amino acid sequence alignment of POU specific, linker, and POU homeodomain of Oct-1 and Oct-4. Amino acids numeration are taken from Herr and Cleary (1995). Dots represents identical amino acids found in Oct-4. α -Helices are indicated by boxes. (D) Schematic representation of Oct-4 and Pit-1 homodimers. Each molecule is given one color.

Thr residues can be phosphorylated *in vitro* by protein kinase A (Kapiloff et al. 1991; Segil et al. 1991) and *in vivo* by a cell-cycle-dependent kinases (Segil et al. 1991; Caelles et al. 1995). In the case of the Oct-4 dimer, phosphorylation of POU_{HD} Ser-7 should interfere with dimer formation on the PORE. Because Oct-1, Oct-2, and Oct-6 can also form a dimer on PORE (Fig. 5A; unpubl.), a reduction of dimer formation attributable to phosphorylation at position 7 of POU_{HD} could be generally valid for all POU factors. In contrast, phosphorylation at position 7 should not interfere with Pit-1 dimerization on the ATGTATATACAT sequence.

Regulation of *OPN* by Oct-4 and Sox-2

Our data show that a short fragment of *i-opn* contains DNA-binding sites for Oct-4 and Sox-2 in close proximity and is sufficient to drive expression of reporters in F9 EC cell lines. The intron fragment of *OPN* is enriched in $\alpha 4$ immunoprecipitates of cross-linked F9 EC cell chromatin. Because the F9 EC cell line shares many characteristics with cells of the preimplantation embryo, we have proposed that Oct-4 and Sox-2 regulate expression of the *OPN* gene during preimplantation stages of embryogenesis by binding to specific DNA sequences in *i-opn* (Strickland and Mahdavi 1978; Strickland et al.

1980; Hogan et al. 1981). Oct-4 mRNA is expressed at comparable levels in cells of the morulae, in the ICM of blastocysts, and in the epiblast of day 5.5 and 6.5 embryo (Schöler et al. 1990a; Yeom et al. 1991). In contrast, *OPN* expression changes during these early stages of development. Weak *OPN* expression is detected in the morulae (Fig. 3B). The highest expression level of *OPN* is observed in the ICM/hypoblast of day 4.0 and 4.5 blastocysts (Fig. 3B,C). After these stages, *OPN* is down-regulated (Fig. 3C). This could be attributable to additional transcription factors that interact with Oct-4 on the intron enhancer. Either a repressive or an activating co-factor could account for the relatively variable *OPN* expression during early embryonic development.

Sox-2 is one candidate for a modulator of Oct-4 transcription. Sox-2 expression varies in different embryonic cell types, which correlates inversely with the expression pattern of *OPN* in these cells (Fig. 6A). In transient transfection assays, the PORE but not the octamer motif is active (Fig. 5D). The activity of the PORE region is increased two- to threefold when the Sox-binding site is included (Fig. 6B, cf. 6 \times O and 6 \times OS). However, this increase is not attributable to Sox-2 because a 20-fold activation was achieved when the Sox-2-binding site was mutated (Fig. 6B). Furthermore, cotransfection experiments in differentiated cells indicate that Sox-2 can re-

Botquin et al.

press Oct-4-mediated *i-opn* activity in a dose-dependent manner (Fig. 6E). Repression requires Sox-2 binding to DNA and also depends on the carboxy-terminal region of Sox-2 that has been described previously as a transactivation domain (Fig. 6F,H; Yuan et al. 1995). Repression of the *i-opn* enhancer by Sox-2 is in contrast to what has been shown for the *fgf-4* 3' enhancer, where Sox-2 stimulates Oct-4-mediated activity (Yuan et al. 1995).

Varying the level or activity of Sox-2 and Oct-4 in embryonic cells is likely to result in altered expression of genes such as *fgf-4* and *OPN*. Changes in *Oct-4*, *Sox-2*, and *OPN* expression levels that occur during differentiation of F9 EC cells are consistent with the model of Oct-4 and Sox-2 interaction on *i-opn* that was established from binding and transactivation data. Sox-2 levels decline rapidly, whereas Oct-4 levels decline more slowly during F9 differentiation (Fig. 7B). Thus, Sox-2-mediated repression of Oct-4 activation of *i-opn* is relieved briefly, resulting in the transient increase of *OPN* expression (Fig. 7A). Forty-eight hours after RA treatment, *Oct-4* is no longer expressed, leading to the loss of a complex at the PORE, which would likely result in low or undetectable levels of *OPN* mRNA production (Fig. 7A).

Sox-2 is not likely to be the only transcription factor involved in modulating the Oct-4-mediated transactivation of the intron enhancer. This would explain why the PORE/octamer region is much weaker than a fragment that is longer and contains a mutated Sox element (Fig. 6B, cf. 6 × O and 6 × OS).

Possible role of *OPN* in the preimplantation embryo

The formation of the hypoblast and its derivatives, parietal and visceral endoderm, depends on interactions between the ECM and integrins (Behrendtsen et al. 1995). *OPN* binds to cells displaying the $\alpha_v\beta_1$, $\alpha_v\beta_3$, and $\alpha_v\beta_5$ integrins on their surface and contains a GRGDS amino acid motif that is absolutely required for the integrin interaction (for review, see Eble and Kühn 1997). Deletion of the β_1 integrin gene in mice results in ICM failure and peri-implantation lethality, indicating that β_1 integrin is required for preimplantation development (Fässler and Meyer 1995; Stephens et al. 1995).

OPN may bind to integrins in a way that alters cell-cell adhesion properties selectively. High levels of *OPN* expression in the 4.0-dpc ICM and forming hypoblast could result in the loosening of cell-cell and cell-ECM contacts. *OPN*-deficient embryos exhibit no apparent phenotype (Hynes 1996) suggesting that loss of *OPN* function during embryogenesis can be compensated by other ECM proteins. Bone sialoprotein II (BSP II) is one possible candidate. Further analyses will be done to define other genes that are also up-regulated transiently by Oct-4 in the developing hypoblast.

Materials and methods

Embryo collection, cell culture, and transient transfection

Morulae and blastocysts were flushed from CD1 mice in M2

medium as described in Hogan et al. (1994). COS, 3T3, 293, and F9 EC cells were grown in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% fetal calf serum (FCS). P19 EC and GCLB cells were maintained in DMEM supplemented with 10% FCS and 1% nonessential amino acids (Seromed). MBL-1 ES cells were cultured in DMEM [0.45% glucose (wt/vol)], 15% FCS, 1 μ M β -ME, and in the presence of 1000 U/ml leukemia inhibitory factor (LIF, GIBCO-BRL). Murine EC and ES cells were grown on 0.1% gelatin-coated tissue culture plates. P19 EC cells were induced to differentiate by treatment with 1 μ M all-*trans* RA (Sigma). Differentiation of F9 cells into parietal endoderm was accomplished by adding 0.1 μ M RA to adherent cells. Differentiation of F9 cells into visceral endoderm was performed by growing the cells for 48 hr in suspension using bacterial Petri dishes. Aggregates were transferred to tissue culture dishes allowing cells to attach to a surface for further growth. Medium containing RA was changed every 24 hr.

Cells were transfected using the calcium-phosphate precipitation method at a density of 3×10^5 cells per 6-cm dish. Each dish received a total of 12 μ g of DNA including 10 μ g of luciferase reporter plasmid and 2 μ g of human β -actin-LacZ as internal standard. In cotransfection assays, 1 μ g of luciferase reporter plasmid and varied amounts of expression plasmids were used in combination with pBluescript KS (Stratagene) to bring the final DNA concentration to 12 μ g. All experiments were carried out four times. After 40 hr of transfection, cells were harvested and 50- μ l extracts were prepared in ice-cold 250 mM Tris (pH 7.8), 1 mM DTT. All luciferase activities were normalized by β -galactosidase expression levels.

Plasmid constructions

The *i-opn* and *i-opn* mut fragment were generated by PCR amplification of osteopontin intron 1 using 1 μ g of F9 genomic DNA, 5'-TATTAGTCCAAATAGAACATC-3' and 5'-TATTAGTCCAAATAGAACATCTTACTCAAATTCAAAGATATCTTTGTTTCTTTCAGCTTTGTATAATGTAAGTTAAATCACATTGCACAAGCAAGCGG-3' as sense primer, respectively, and 5'-CTCTCATCCTTAGCAAGGAA-3' as antisense primer. The conditions were the same as described for PCR of immunoprecipitated cross-linked chromatin. The *i-opn* was precloned into the PCR II vector using the TA Cloning kit (Invitrogen). The *i-opn* was cut out of the PCR II vector by *Eco*RI and was recloned into the *Eco*RI site of pBluescript KS. After *Hind*III-*Bam*HI digestion, the *i-opn* of pBluescript KS was cloned into *Hind*III-*Bam*HI site of -37tk luc (kindly provided by A. Hecht, ZMBH, Heidelberg, Germany). The 6 × O, 10 × O, 6 × O⁻¹, 6 × O⁻², 6 × O⁻³, 6 × O⁻⁴, 6 × OS, 6 × O^{-S}, and 6 × OS⁻ reporter plasmids were obtained by multimerizing the corresponding oligonucleotides. The 5' overhang of the multimers were filled in using Klenow polymerase and fragments of 6 or 10 oligonucleotide repeats were precloned into the *Eco*RV site of pBluescript KS. The *Hind*III-*Bam*HI fragment containing the oligonucleotide multimer was cut out of the pBluescript KS and was inserted into *Hind*III-*Bam*HI sites of -37tk luc.

Labeling, cross-linking, and shearing chromatin

Proteins were labeled by adding 175 μ Ci/ml [³⁵S]methionine (labeling grade; Amersham) 1–2 hr before harvest. In vivo fixation of chromatin was done as described by Orlando and Paro (1993) with several modifications. Cells were removed from the plates by trypsin, resuspended at a density of 5×10^6 cells/ml in DMEM/5% heat-inactivated FCS, and fixed in vivo by adding one-tenth volume of formaldehyde buffer [11% formaldehyde (vol/vol) in 10% methanol, 0.1 M NaCl, 1 mM Na-EDTA, 0.5

New Oct-4 dimerization in OPN preimplantation enhancer

mm Na-EGTA (pH 8.0), 50 mM Tris-HCl (pH 8.0)]. The fixation reaction was incubated 10 min at room temperature thoroughly mixed on ice for 40 min, and stopped by adding glycine (125 mM final concentration). Fixed cells were collected by centrifugation (500g for 10 min at 4°C) and resuspended on a roller for 10 min at 4°C in 40 ml Triton-washing buffer [0.25% Triton X-100, 10 mM Na-EDTA, 0.5 mM Na-EGTA, 10 mM Tris-HCl (pH 8.0)] to lyse unfixed cells. Fixed chromatin was collected by centrifugation at 500g for 10 min at 4°C, washed in 40 ml of NaCl washing buffer [200 mM NaCl, 1 mM Na-EDTA, 0.5 mM Na-EGTA, 10 mM Tris-HCl (pH 8.0)] for 10 min at 4°C, centrifuged again, resuspended in 2–3 ml of TE-EGTA buffer [1 mM Na-EDTA, 0.5 mM Na-EGTA, 10 mM Tris-HCl (pH 8.0)], transferred to siliconized Corex-glass tubes, and ~0.5 ml of glass microbeads (diameter of 0.10–0.11 mm; B. Braun Biotech International) were added to every 3 ml of cell suspension. The mixture was sonified on ice for 15 min with the Branson model B15 at a “duty cycle” of 0.65% with the output control set at 7–7.5 to produce DNA fragments of an average size of 500 bp, with a maximum size of 2.5 kb. Samples were adjusted to 0.5% Sarkosyl and gently swirled for 10 min at room temperature. Cell debris was eliminated by two 15-min centrifugation steps at 15,000g at 4°C.

Purification, immunoprecipitation, and decross-linking of fixed chromatin fragments

Cross-linked chromatin complexes were separated from free proteins, DNA, and RNA by CsCl isopycnic centrifugation. Samples were adjusted to 1.42 gram/ml CsCl, brought to 5 ml with the TE-EGTA-Sarkosyl buffer, and centrifuged in a Beckman SW55Ti rotor at 40,000 rpm for 72 hr at 20°C. Fractions of 300 μ l were collected from the bottom of the gradient using a 0.25-mm capillary needle and ³⁵S content was measured in a Beckman LS 6000 SC scintillation counter. Fractions containing the cross-linked chromatin (~1.38 gram/ml) were pooled and dialyzed overnight at 4°C against 5% glycerol, 1 mM Na-EDTA, 0.5 mM Na-EGTA, 10 mM Tris-HCl (pH 8.0). Fixed chromatin can be stored in this buffer for at least 3 months at -80°C and small aliquots were used for immunoprecipitations.

Aliquots (200 μ g of cross-linked chromatin in 100 μ l) were cleared by centrifugation (15 min at 13,000 rpm), mixed with 30 μ l H₂O and 100 μ l 2 \times TE-EGTA buffer, carefully adjusted to 0.1% SDS (wt/vol) and 0.5 M NaCl, incubated for 5 min at room temperature, adjusted to 1% Triton X-100 (wt/vol), 0.1% Na-Deoxycholate and 0.1% BSA, incubated for 10 min, and cleared again by centrifugation for 15 min at 13,000 rpm. As a preclearing step, supernatants were incubated with 100 μ l of Dynabeads coupled to sheep anti-rabbit IgG (6 \times 10⁸ to 7 \times 10⁸ beads/ml; Dynal) for 1 hr. Supernatants were removed from beads by a magnetic particle concentrator (MPC; Dynal) and 10 μ g of specific antibodies against Oct-4 (or IgG of preimmune serum) were added. Samples were rotated for 3 hr at 4°C, 300 μ l of sheep anti-rabbit IgG Dynabeads added, incubated with rotation for 2 hr at 4°C, and immunocomplexes were pelleted by magnetic field. Pellets were washed (10 min per wash) five times in 1 ml of washing buffer [1% Triton X-100 (wt/vol), 0.1% Na-deoxycholate (wt/vol), 0.1% SDS (wt/vol), 0.1% BSA (wt/vol), 0.5 M NaCl, 1 mM Na-EDTA, 0.5 mM Na-EGTA, 10 mM Tris-HCl (pH 8.0)], once with 1 ml of LiCl-washing buffer [250 mM LiCl, 0.5% NP-40 (wt/vol), 0.5% Na-deoxycholate (wt/vol), 1 mM Na-EDTA, 0.5 mM Na-EGTA, 10 mM Tris-HCl (pH 8.0)], twice with 1 ml of TE-EGTA buffer, and resuspended in 350 μ l of TE-EGTA buffer. One hundred microliters were kept for protein analysis, and 250 μ l was treated 30 min at 37°C with DNase-

free RNase A (50 μ g/ml) and incubated overnight at 37°C in 250 μ g/ml proteinase K/0.25% SDS.

PCR on immunoprecipitated cross-linked chromatin

PCR amplification was performed in a final volume of 100 μ l, using 1 ng of genomic F9 DNA or 1 ng of immunoprecipitated cross-linked chromatin as template, 10 pmoles of each primer, 2.5 mM dNTPs (Pharmacia), 2.5 units of *Taq* DNA polymerase (Perkin Elmer-Cetus); and 1 \times PCR buffer (Perkin Elmer-Cetus). The PCR consisted of 30 cycles of 1 min at 94°C, 1 min at 55°C, and 1 min at 72°C. Upstream and downstream primers pairs were as follows: OPN intron 1, 5'-CAAATTCAAAGATATC-TTTGTTTC-3', 5'-CCCCACTATCTGATGTCTCT-3'; OPN exon 7, 5'-ATCCTGATGCCACAGATGAG-3', 5'-ACTTGTG-GCTCTGATGTTCC-3'; G6PD fragment, 5'-AAGCCAACT-AGCAGCTAGG-3', 5'-GGGCTAGTCTATCATTGCAG-3'.

Preparation of protein extracts and EMSA

Extraction of proteins and EMSA conditions used for Oct-4 and Sox-2-binding analysis were carried out as described in Sylvester and Schöler (1994) and Dailey et al. (1994), respectively.

Oligonucleotides used in this study

Bold indicates introduced mutation, lowercase letters indicates non-OPN sequences. **O**, 5'-ctgaAAGTTAAAATCACATTT-GAAATGCAAATGGAAAAGCaagtcga-3'; **O⁻¹**, 5'-ctgaAAGT-TAAAATCACATTTGAAAGGCAAATGGAAAAGCaagtcga-3'; **O⁻²**, 5'-ctgaAAGTTAAAATCACATGTGAAAGGCAAAT-GGAAAAGCaagtcga-3'; **O⁻³**, 5'-ctgaAAGTTAAAATCACAT-GTGAAATGCAAATGGAAAAGCaagtcga-3'; **O⁻⁴**, 5'-ctgaAA-GTTAAAATCACATTTGAAATGCAAATGGAAAAGCaagtcga-3'; **OS**, 5'-ctgaTCTTTGTTTCTTTTCAGCTTTGTATAATG-TAAGTTAAAATCACATTTGAAATGCAAATGGAAAAGCaagtcga-3'; **O^{-S}**, 5'-ctgaTCTTTGTTTCTTTTCAGCTTTGTAT-AATGTAAGTTAAAATCACATTTGAAATGCAAATGGAAAAGCaagtcga-3'; **OS_a⁻**, 5'-ctga**TGCACTGACCTTT**CAGC-TTTGTATAATGTAAGTTAAAATCACATTTGAAATGCA-AATGGAAAAGCaagtcga-3'; **OS_b⁻**, 5'-ctgaTCTCTGTCTTT-CAGCTTTGTATAATGTAAGTTAAAATCACATTTGAA-ATGCAAATGGAAAAGCaagtcga-3'; **P-1**, 5'-ctgaAAGTTAA-AATCACATTTGAAATGCAAATGGAAAAGCaagtcga-3'; **P+1**, 5'-ctgaAAGTTAAAATCACATTTGATAATGCAAATGGAA-AAGCaagtcga-3'.

RNA extraction and Northern blot analyses

Poly(A)⁺ RNA was isolated from cell lines using the Oligotex mRNA kit (Qiagen). Total cellular RNA was prepared by the guanidinium thiocyanate-phenol extraction procedure described in Chomczynski and Sacchi (1987). Northern blot analysis of poly(A)⁺ and total RNA was performed as described elsewhere (Kroczyk 1993). Hybond-N⁺ filters (Amersham) were hybridized using a *Pst*I-*Pst*I Oct-4 probe (400-bp fragment corresponding to the 5' end of the cDNA) (10⁶ cpm/ml), a *Hin*dIII-*Hin*dIII OPN probe (position +157 to +1144 of the cDNA) (2 \times 10⁶ cpm/ml) (2AR plasmid, kindly provided by D. Denhardt, Rutgers University, Piscataway, NJ), or an oligonucleotide 28 S probe: 5'-CAGCGAGCCGGGCTTCTTACCCATT-TAAAGTTTGAGAATAGGTGGAGATCG-3' (0.5 \times 10⁶ cpm/ml; kindly provided M. Muckenthaler, EMBL). Northern blots were analyzed for band intensity using the PhosphorImager (Molecular Dynamics).

Botquin et al.

RNA isolation from preimplantation embryos and RT-PCR

Ten embryos were suspended in 200 μ l of RNazol (Tel-test, Inc.) and 20 μ l of chloroform while on ice by shaking. The suspension was left on ice 5 min and cleared by centrifugation (12,000g for 15 min at 4°C), and total RNA was precipitated for 15 min on ice after adding 1 volume of isopropanol and 2 μ l of glycogen (Boehringer Mannheim; 20 mg/ml stock), collected by centrifugation (12,000g for 15 min at 4°C), washed with 70% ethanol, and dissolved in 11 μ l of DEPC-H₂O. Reverse transcription was performed for 1 hr at 37°C in a total volume of 20 μ l by adding 9 μ l of the following mix to the dissolved RNA: 0.5 μ g of oligo(dT) (Promega), 39 units of RNasin (Promega), 1 mM dNTPs (Pharmacia), 1 \times RT-buffer, and 200 units of reverse transcriptase (M-MLV; Promega). PCR was performed using 5 μ l of the RT reaction as template for a 25 μ l final reaction volume. Each reaction contained: 10 pmoles of each primer, 2.5 mM dNTPs, 2.5 units of *Taq* polymerase (Perkin Elmer-Cetus), and 1 \times PCR buffer (Boehringer Mannheim). The PCR consisted of 35 cycles of 30 sec at 94°C, 1 min at 62°C, and 1 min at 72°C. Upstream and downstream primers were as follows: Oct-4, 5'-GGCGTTCTCTTTGGAAAGGTGTTTC-3' and 5'-CTCGAAC-CACATCCTTCTCT-3' (spanning exons 2-3 and 4-5, respectively); OPN, 5'-GCAGACACTTTCCTCAATCG-3' and 5'-GCCCTTCCGTTGTGCTG-3' (located in exon 6 and exon 7, respectively).

Riboprobe synthesis and whole mount in situ hybridization of 3.5-6.5 dpc embryos

The 1-kb OPN cDNA cloned in pGEM3 (2AR plasmid) was excised with *Hind*III from the vector and recloned in the same vector so that both orientations were available from the same promoter. Vectors were linearized with *Eco*RI, both sense and antisense riboprobes were generated by SP6 RNA polymerase and DIG-labeling mix according to the manufacturer (Boehringer Mannheim), reactions were digested with RNase-free DNase I (Promega) for 15 min at 37°C, ethanol precipitated in the presence of 4 M LiCl, and resuspended in DEPC-H₂O. The concentration and labeling efficiency of the probes were determined empirically by agarose gel electrophoresis and by dot-blot analyses, respectively.

In situ hybridization of embryos was performed as described by MacPhee et al. (1994) and Rosen and Beddington (1993), with some modifications. Embryos were fixed for 3 hr in 3% paraformaldehyde/0.5% glutaraldehyde in PBS, washed in PBS, permeabilized for 20 min at 4°C in PBT (PBS with 0.1% Triton X-100), digested 15 min with proteinase K (1 μ g/ml in PBT), washed twice for 5 min in fresh glycine (2 mg/ml PBT), refixed for 30 min in 4% paraformaldehyde/0.2% glutaraldehyde in PBS, briefly washed in triethanolamine buffer (100 mM, pH 8.0) (Sigma), treated three times for 5 min with 0.25% acetic anhydride (Sigma) in triethanolamine buffer and once for 20 min with 0.1% sodium borohydride (Sigma) in PBT. After prehybridization in 50% formamide, 0.75 M NaCl, 10 mM Pipes (pH 6.8), 1 mM EDTA, 100 mg/ml yeast tRNA, 0.1% BSA, 1% SDS for 2 hr at 50°C, embryos were hybridized for 34 hr in the same solution containing 1 μ g/ml riboprobe. Embryos were rinsed briefly and washed extensively (20 hr at 60°C) in washing buffer 1 [300 mM NaCl, 1% SDS in PE buffer (10 mM PIPES at pH 6.8, 1 mM EDTA)], washed two times for 30 min in washing buffer 2 (50 mM NaCl, 0.1% SDS in PE buffer), and incubated once for 30 min at 37°C with 100 μ g/ml RNase A diluted in the appropriate buffer [500 mM NaCl, 10 mM PIPES (pH 7.2), 0.1% Triton X-100]. Embryos were then washed for 45 min at 50°C in washing buffer 3 (50% formamide, 300 mM NaCl, 1% SDS in PE buffer),

for 30 min at 50°C in washing buffer 4 (50% formamide, 150 mM NaCl, 0.1% Triton X-100 in PE buffer), and finally 30 min followed by 20 min in washing buffer 5 (500 mM NaCl, 0.1% Triton X-100 in PE buffer) at 70°C. Embryos were blocked for 1 hr at room temperature in maleic acid washing buffer [100 mM maleic acid, 150 mM NaCl (pH 7.5)] containing 2% heat-inactivated sheep serum and 2% blocking buffer (Boehringer Mannheim, cat. no. 1175041) and incubated overnight at 4°C with anti-digoxigenin Fab-alkaline phosphatase conjugate antibody (Boehringer Mannheim) diluted 1:2000. Excess antibody was removed by washing the embryos three times for 5 min and then four times for 30 min with 1 \times TBST at room temperature. Embryos were then equilibrated in alkaline phosphatase buffer [100 mM NaCl, 50 mM MgCl₂, 0.1% Tween-20, 100 mM Tris (pH 9.5)] and stained at room temperature in the dark with BM purple (Boehringer Mannheim, cat. no. 1442074). Color reaction was stopped by washing the embryos with PBS. Uteri from 5.5 and 6.5 dpc pregnant females were fixed with 4% paraformaldehyde, dehydrated and embedded in paraffin wax. Sections of 6 μ m were transferred to silone-coated slides. Treatment of the slides and hybridization were performed using the components and the protocol of Novagen (SureSite II system). After several washing steps, the slides were blocked and incubated overnight at 4°C with 1:500 anti-DIG in blocking buffer. Slides were washed four times for 30 min each with maleic acid washing buffer and stained with BM purple.

Computer searches and modeling

Identification of genes containing combination of octamer and Sox binding motifs was performed using the prepGCG program, findpatterns, and GenBank/EMBL database.

Homology modeling of Oct-4 dimer configuration was based on Oct-1 as template structure (Klemm et al. 1994). Modeling was performed using WHAT IF programme (Vriend 1990) and modeling protocol was used as described in Vriend and Eijnsink (1993). There is no structure template available for the amino terminus, carboxyl terminus, and linker. For this reason, these parts of the molecule are not represented on the model.

The DNA was modeled by maintaining the phosphate and the sugar backbone of the DNA in the Oct-1 template structure. The bases were replaced using the corresponding bases found in the PORE DNA and were modeled to fall in the same plane as the corresponding Oct-1 bases with ideal geometry.

The Oct-4 dimer was constructed by optimally superposing the GCAAAT sequence of the octamer motif on which Oct-4 was modeled, onto the AGTTTA sequence. The RMS deviation of the DNA superposition is \sim 1.3 Å, which implies an uncertainty in the overall location of the second Oct-4 with respect to the first Oct-4 of \sim 1-12 Å. The average local coordinate error is expected to be \sim 1.5 Å (Chinea et al. 1995).

Acknowledgments

We are most grateful to Drs. V. Orlando and R. Paro for a thorough introduction to and sound advice on the chromatin precipitation procedures. We thank Dr. L. Dailey for Sox-2 expression vectors and antibodies, Dr. L. Toldo for computer search, M. Pesce for reading the manuscript, and U. Schibler for a valuable comment. We also thank K. Hübner for Oct-4 protein and antibody, C. Sandberg for RNA purification. H.H. was supported by the Deutsche Studienstiftung and Fond der chemischen Industrie, K.A., V.B., and M.K.G. by the European Community (EU contracts CT92-0073 and BIO4-CT95-0284), G.F. by the CNRS.

The publication costs of this article were defrayed in part by payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 USC section 1734 solely to indicate this fact.

References

- Adamson, E.D. 1986. Cell-lineage-specific gene expression in development. In *Experimental approaches to mammalian embryonic development* (ed. J. Rossant and R.A. Pederson), pp. 321–364. Cambridge University Press, Cambridge, UK.
- Ambrosetti, D.C., C. Basilico, and L. Dailey. 1997. Synergistic activation of the fibroblast growth factor 4 enhancer by Sox2 and Oct-3 depends on protein-protein interactions facilitated by a specific spatial arrangement of factor binding sites. *Mol. Cell Biol.* **17**: 6321–6329.
- Behrendtsen, O., C.M. Alexander, and Z. Werb. 1995. Cooperative interactions between extracellular matrix, integrins and parathyroid hormone-related peptide regulate parietal endoderm differentiation in mouse embryos. *Development* **121**: 4137–4148.
- Caelles, C., H. Hennemann, and M. Karin. 1995. M-phase-specific phosphorylation of the POU transcription factor GHF-1 by a cell cycle-regulated protein kinase inhibits DNA binding. *Mol. Cell Biol.* **15**: 6694–6701.
- Chinea, G., G. Padron, R.W. Hooft, C. Sander, and G. Vriend. 1995. The use of position-specific rotamers in model building by homology. *Proteins* **23**: 415–421.
- Chomczynski, P. and N. Sacchi. 1987. Single-step method of RNA isolation by acid guanidinium thiocyanate phenol chloroform extraction. *Anal. Biochem.* **162**: 156–159.
- Collignon, J., S. Sockanathan, A. Hacker, M. Cohen-Tannoudji, D. Norris, S. Rastan, M. Stevanovic, P.N. Goodfellow, and R. Lovell-Badge. 1996. A comparison of the properties of Sox-3 with Sry and two related genes, Sox-1 and Sox-2. *Development* **122**: 509–520.
- Curatola, A.M. and C. Basilico. 1990. Expression of the K-fgf proto-oncogene is controlled by 3' regulatory elements which are specific for embryonal carcinoma cells. *Mol. Cell Biol.* **10**: 2475–2484.
- Dailey, L., H. Yuan, and C. Basilico. 1994. Interaction between a novel F9-specific factor and octamer-binding proteins is required for cell-type-restricted activity of the fibroblast growth factor 4 enhancer. *Mol. Cell Biol.* **14**: 7758–7769.
- Denhardt, D.T. and X. Guo. 1993. Osteopontin: A protein with diverse functions. *FASEB J.* **7**: 1475–1482.
- Denhardt, D.T., W.T. Butler, A.F. Chambers, and D.R. Senger. 1995. Gene expression and phosphorylation of mouse osteopontin. In *Osteopontin: Role in cell signaling and adhesion* (ed. D.T. Denhardt, W.T. Butler, A.F. Chambers, and D.R. Senger). The New York Academy of Sciences, New York, NY.
- Eble, J.A. and K. Kühn. 1997. In *Integrin-ligand interaction* (ed. J.A. Eble and K. Kühn). Springer-Verlag, Heidelberg, Germany.
- Fässler, R. and M. Meyer. 1995. Consequences of lack of $\beta 1$ integrin gene expression in mice. *Genes & Dev.* **9**: 1896–1908.
- Feldman, B., W. Poueymirou, V.E. Papaioannou, T.M. DeChiara, and M. Goldfarb. 1995. Requirement of FGF-4 for postimplantation mouse development. *Science* **267**: 246–249.
- Ferrari, S., V.R. Harley, A. Pontiggia, P.N. Goodfellow, R. Lovell-Badge, and M.E. Bianchi. 1992. SRY, like HMG 1, recognizes sharp angles in DNA. *EMBO J.* **11**: 4497–4506.
- Fujii, H. and H. Hamada. 1993. A CNS-specific POU transcription factor, Brn-2, is required for establishing mammalian neural cell lineages. *Neuron* **11**: 1197–1206.
- Gardner, R.L. 1983. Origin and differentiation of extraembryonic tissues in the mouse. *Int. Rev. Exp. Pathol.* **24**: 63–133.
- Giese, K., J. Cox, and R. Grosschedl. 1992. The HMG domain of lymphoid enhancer factor 1 bends DNA and facilitates assembly of functional nucleoprotein structures. *Cell* **69**: 185–195.
- Herr, W. and M.A. Cleary. 1995. The POU domain: Versatility in transcriptional regulation by a flexible two-in-one DNA-binding domain. *Genes & Dev.* **9**: 1679–1693.
- Hogan, B.L.M., A. Taylor, and E. Adamson. 1981. Cell interactions modulate embryonal carcinoma cell differentiation into parietal and visceral endoderm. *Nature* **291**: 235–237.
- Hogan, B.L.M., R. Beddington, F. Constantini, and E. Lacy. 1994. Section I: In vitro culture of eggs, embryos, primordial sperm cells and teratocarcinoma cells. In *Manipulating the mouse embryo. A laboratory manual* (ed. B.L.M. Hogan, R. Beddington, F. Constantini, and E. Lacy), 2nd ed., p. 386. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
- Hynes, R.O. 1996. Targeted mutations in cell adhesion genes: What have we learned from them? *Dev. Biol.* **180**: 402–412.
- Jacobson, E.M., P. Li, A. Leon-del-Rio, M.G. Rosenfeld, and A.K. Aggarwal. 1997. Structure of Pit-1 POU domain bound to DNA as a dimer: Unexpected arrangement and flexibility. *Genes & Dev.* **11**: 198–212.
- Kapiloff, M.S., Y. Farkash, M. Wegner, and M.G. Rosenfeld. 1991. Variable effects of phosphorylation of Pit-1 dictated by the DNA response elements. *Science* **253**: 786–789.
- Klemm, J.D. and C.O. Pabo. 1996. Oct-1 POU domain-DNA interactions: Cooperative binding of isolated subdomains and effects of covalent linkage. *Genes & Dev.* **10**: 27–36.
- Klemm, J.D., M.A. Rould, R. Aurora, W. Herr, and C.O. Pabo. 1994. Crystal structure of the Oct-1 POU domain bound to an octamer site: DNA recognition with tethered DNA-binding modules. *Cell* **77**: 21–32.
- Kraft, H.J., S. Mosselman, H.A. Smits, P. Hohenstein, E. Piek, Q. Chen, K. Artzt, and E.J. van Zoelen. 1996. Oct-4 regulates alternative platelet-derived growth factor alpha receptor gene promoter in human embryonal carcinoma cells. *J. Biol. Chem.* **271**: 12873–12878.
- Kroczyk, R.A. 1993. Southern and Northern analysis. *J. Chromatogr.* **618**: 133–145.
- Leger, H., E. Sock, K. Renner, F. Grummt, and M. Wegner. 1995. Functional interaction between the POU domain protein Tst-1/Oct-6 and the high-mobility-group protein HMG-I/Y. *Mol. Cell Biol.* **15**: 3738–3747.
- Liu, L. and R.M. Roberts. 1996. Silencing of the gene for the beta subunit of human gonadotropin by the embryonic transcription factor Oct 3/4. *J. Biol. Chem.* **271**: 16683–16689.
- MacPhee, D.J., K.J. Barr, P.A. De Sousa, S.D. Todd, and G.M. Kidder. 1994. Regulation of Na⁺, K⁺-ATPase alpha subunit gene expression during mouse preimplantation development. *Dev. Biol.* **162**: 259–266.
- Nadijcka, M. and N. Hillman. 1974. Ultrastructural studies of the mouse blastocyst substages. *J. Embryol. Exp. Morphol.* **32**: 675–695.
- Niswander, L. and G.R. Martin. 1992. Fgf-4 expression during gastrulation, myogenesis, limb and tooth development in the mouse. *Development* **114**: 755–768.
- Nomura, S., A.J. Wills, D.R. Edwards, J.K. Heath, and B.L. Hogan. 1988. Developmental expression of 2ar (osteopontin) and SPARC (osteonectin) RNA as revealed by in situ hybridization. *J. Cell Biol.* **106**: 441–450.
- Okamoto, K., H. Okazawa, A. Okuda, M. Sakai, M. Muramatsu,

Botquin et al.

- and H. Hamada. 1990. A novel octamer binding transcription factor is differentially expressed in mouse embryonic cells. *Cell* **60**: 461–472.
- Orlando, V. and R. Paro. 1993. Mapping Polycomb-repressed domains in the bithorax complex using in vivo formaldehyde cross-linked chromatin. *Cell* **75**: 1187–1198.
- Palmieri, S.L., W. Peter, H. Hess, and H.R. Schöler. 1994. Oct-4 transcription factor is differentially expressed in the mouse embryo during establishment of the first two extraembryonic cell lineages involved in implantation. *Dev. Biol.* **166**: 259–267.
- Pesce, M., X. Wang, D.J. Wolgemuth, and H.R. Schöler. 1998a. Differential expression of the Oct-4 transcription factor during mouse germ cell differentiation. *Mech. Dev.* **71**: 89–98.
- Pesce, M., M.K. Gross, and H.R. Schöler. 1998b. In line with our ancestors: Oct-4 and the mammalian germ. *BioEssays* (in press).
- Pruitt, S.C. 1994. Primitive streak mesoderm-like cell lines expressing Pax-3 and Hox gene autoinducing activities. *Development* **120**: 37–47.
- Rizzino, A. and E. Rosfjord. 1994. Transcriptional regulation of the murine k-fgf gene. *Mol. Reprod. Dev.* **39**: 106–111.
- Robertson, E. 1987. Cell culture methods and induction of differentiation of embryonal carcinoma. In *Teratocarcinomas and embryonic stem cells. A practical approach*, pp. 19–50. IRL Press, Oxford, UK.
- Rosen, B. and R.S. Beddington. 1993. Whole-mount in situ hybridization in the mouse embryo: Gene expression in three dimensions. *Trends Genet.* **9**: 162–167.
- Rosfjord, E. and A. Rizzino. 1994. The octamer motif present in the Rex-1 promoter binds Oct-1 and Oct-3 expressed by EC cells and ES cells. *Biochem. Biophys. Res. Commun.* **203**: 1795–1802.
- Rosner, M.H., M.A. Viganò, K. Ozato, P.M. Timmons, F. Poirier, P.W. Rigby, and L.M. Staudt. 1990. A POU-domain transcription factor in early stem cells and germ cells of the mammalian embryo. *Nature* **345**: 686–692.
- Ryan, A.K. and M.G. Rosenfeld. 1997. POU domain family values: Flexibility, partnerships, and developmental codes. *Genes & Dev.* **11**: 1207–1225.
- Saijoh, Y., H. Fujii, C. Meno, M. Sato, Y. Hirota, S. Nagamatsu, M. Ikeda, and H. Hamada. 1996. Identification of putative downstream genes of Oct-3, a pluripotent cell-specific transcription factor. *Genes Cells* **1**: 239–252.
- Schöler, H.R. 1991. Octomania: The POU factors in murine development. *Trends Genet.* **7**: 323–329.
- Schöler, H.R., R. Balling, A.K. Hatzopoulos, N. Suzuki, and P. Gruss. 1989a. Octamer binding proteins confer transcriptional activity in early mouse embryogenesis. *EMBO J.* **8**: 2551–2557.
- Schöler, H.R., A.K. Hatzopoulos, R. Balling, N. Suzuki, and P. Gruss. 1989b. A family of octamer-specific proteins present during mouse embryogenesis: Evidence for germ line-specific expression of an Oct factor. *EMBO J.* **8**: 2543–2550.
- Schöler, H.R., G.R. Dressler, R. Balling, H. Röhde, and P. Gruss. 1990a. Oct-4: A germline-specific transcription factor mapping to the mouse t-complex. *EMBO J.* **9**: 2185–2195.
- Schöler, H.R., S. Ruppert, N. Suzuki, K. Chowdhury, and P. Gruss. 1990b. New type of POU domain in germ line-specific protein Oct-4. *Nature* **344**: 435–439.
- Schöler, H.R., T. Ciesiolka, and P. Gruss. 1991. A nexus between Oct-4 and E1A: Implications for gene regulation in embryonic stem cells. *Cell* **66**: 291–304.
- Schoorlemmer, J. and W. Kruijer. 1991. Octamer-dependant regulation of the kFGF gene in embryonal carcinoma and embryonic stem cells. *Mech. Dev.* **36**: 75–86.
- Segil, N., S.B. Roberts, and N. Heintz. 1991. Mitotic phosphorylation of the Oct-1 homeodomain and regulation of Oct-1 DNA binding activity. *Science* **254**: 1814–1816.
- Solomon, M.J., P.L. Larsen, and A. Varshavsky. 1988. Mapping protein-DNA interactions in vivo with formaldehyde: Evidence that histone H4 is retained on a highly transcribed gene. *Cell* **53**: 937–947.
- Stephens, L.E., A.E. Sutherland, I.V. Klimanskaya, A. Andrieux, J. Meneses, R.A. Pedersen, and C.H. Damsky. 1995. Deletion of $\beta 1$ integrins in mice results in inner cell mass failure and peri-implantation lethality. *Genes & Dev.* **9**: 1883–1895.
- Stickland, S. and V. Mahdavi. 1978. The induction of differentiation in teratocarcinoma stem cells by retinoic acid. *Cell* **15**: 393–404.
- Strickland, S., K.K. Smith, and K.R. Marotti. 1980. Hormonal induction of differentiation in teratocarcinoma stem cells: Generation of parietal endoderm by retinoic acid and dibutyryl cAMP. *Cell* **21**: 347–355.
- Sylvester, I. and H.R. Schöler. 1994. Regulation of the Oct-4 gene by nuclear receptors. *Nucleic Acids Res.* **22**: 901–911.
- Verrijzer, C.P. and P.C. van der Vliet. 1993. POU domain transcription factors. *Biochim. Biophys. Acta* **1173**: 1–21.
- Verrijzer, C.P., J.A. van Oosterhout, W.W. van Weperen, and P.C. van der Vliet. 1991. POU proteins bend DNA via the POU-specific domain. *EMBO J.* **10**: 3007–3014.
- Vriend, G. 1990. WHAT IF: A molecular modeling and drug design program. *J. Mol. Graph.* **8**: 52–56.
- Vriend, G. and V. Eijssink. 1993. Prediction and analysis of structure, stability and unfolding of thermolysin-like proteases. *J. Comput. Aided Mol. Des.* **7**: 367–396.
- Waterhouse, P., R.S. Parhar, X. Guo, P.K. Lala, and D.T. Denhardt. 1992. Regulated temporal and spatial expression of the calcium-binding proteins calyculin and OPN (osteopontin) in mouse tissues during pregnancy. *Mol. Reprod. Dev.* **32**: 315–323.
- Wegner, M., D.W. Drolet, and M.G. Rosenfeld. 1993. POU-domain proteins: Structure and function of developmental regulators. *Curr. Opin. Cell Biol.* **5**: 488–498.
- Werner, M.H., J.R. Huth, A.M. Gronenborn, and G.M. Clore. 1995. Molecular basis of human 46X, Y sex reversal revealed from the three-dimensional solution structure of the human SRY-DNA complex. *Cell* **81**: 705–714.
- Yeom, Y.I., H.-S. Ha, R. Balling, H.R. Schöler, and K. Artzt. 1991. Structure, expression and chromosomal location of the Oct-4 gene. *Mech. Dev.* **35**: 171–179.
- Yeom, Y.I., G. Fuhrmann, C.E. Ovitt, A. Brehm, K. Ohbo, M. Gross, K. Hübner, and H.R. Schöler. 1996. Germline regulatory element of Oct-4 specific for the totipotent cycle of embryonal cells. *Development* **122**: 881–894.
- Yuan, H., N. Corbi, C. Basilico, and L. Dailey. 1995. Developmental-specific activity of the FGF-4 enhancer requires the synergistic action of Sox-2 and Oct-3. *Genes & Dev.* **9**: 2635–2645.
- Zwilling, S., H. König, and T. Wirth. 1995. High mobility group protein 2 functionally interacts with the POU domains of octamer transcription factors. *EMBO J.* **14**: 1198–1208.



New POU dimer configuration mediates antagonistic control of an osteopontin preimplantation enhancer by Oct-4 and Sox-2

Valérie Botquin, Heike Hess, Guy Fuhrmann, et al.

Genes Dev. 1998, **12**:

Access the most recent version at doi:[10.1101/gad.12.13.2073](https://doi.org/10.1101/gad.12.13.2073)

References

This article cites 65 articles, 23 of which can be accessed free at:
<http://genesdev.cshlp.org/content/12/13/2073.full.html#ref-list-1>

License

Email Alerting Service

Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article or [click here](#).

An advertisement banner for Dharmacon Reagents and Horizon. On the left, it says 'Dharmacon Reagents' with the tagline 'Custom synthesis, RNAi, and CRISPR solutions'. In the center, the text 'Infinite Reliability' is prominently displayed in white. To the right, the 'horizon' logo is shown with the tagline 'a PerkinElmer company'. A small 'More' button is visible in the bottom right corner of the banner. The background features a colorful, abstract image of what appears to be a DNA double helix or a similar biological structure.